JP2019506157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506157A5 JP2019506157A5 JP2018537795A JP2018537795A JP2019506157A5 JP 2019506157 A5 JP2019506157 A5 JP 2019506157A5 JP 2018537795 A JP2018537795 A JP 2018537795A JP 2018537795 A JP2018537795 A JP 2018537795A JP 2019506157 A5 JP2019506157 A5 JP 2019506157A5
- Authority
- JP
- Japan
- Prior art keywords
- differentiation
- cardiomyocytes
- stem cells
- rapamycin
- cardiomyocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004413 Myocytes, Cardiac Anatomy 0.000 claims description 133
- 210000002317 cardiac myocyte Anatomy 0.000 claims description 133
- 230000004069 differentiation Effects 0.000 claims description 108
- 239000000203 mixture Substances 0.000 claims description 82
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 59
- 229960002930 sirolimus Drugs 0.000 claims description 57
- 210000000130 stem cell Anatomy 0.000 claims description 52
- 230000037361 pathway Effects 0.000 claims description 40
- -1 small molecule compound Chemical class 0.000 claims description 39
- 230000002401 inhibitory effect Effects 0.000 claims description 37
- 239000003112 inhibitor Substances 0.000 claims description 33
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 28
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 28
- 230000001939 inductive effect Effects 0.000 claims description 25
- 108050003627 Wnt Proteins 0.000 claims description 24
- 102000013814 Wnt Human genes 0.000 claims description 24
- 229960005167 everolimus Drugs 0.000 claims description 20
- 230000001737 promoting Effects 0.000 claims description 16
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 14
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 13
- 230000019491 signal transduction Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- KVLFRAWTRWDEDF-IRXDYDNUSA-N [5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 claims description 10
- 102000004310 Ion Channels Human genes 0.000 claims description 9
- 108090000862 Ion Channels Proteins 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- BUROJSBIWGDYCN-OZFXDLPUSA-N Ridaforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=CC=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-OZFXDLPUSA-N 0.000 claims description 5
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 5
- 201000010238 heart disease Diseases 0.000 claims description 5
- 229960001302 ridaforolimus Drugs 0.000 claims description 5
- 229960000235 temsirolimus Drugs 0.000 claims description 5
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000004027 cells Anatomy 0.000 description 66
- 210000001778 pluripotent stem cell Anatomy 0.000 description 34
- 230000000694 effects Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 23
- 241000766026 Coregonus nasus Species 0.000 description 22
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 22
- 230000002107 myocardial Effects 0.000 description 21
- 239000002609 media Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 12
- 239000001963 growth media Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 10
- 108090001123 antibodies Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 102000004121 Annexin A5 Human genes 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 206010059512 Apoptosis Diseases 0.000 description 7
- HKVAMNSJSFKALM-XJFKSLPYSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)C(C)=C[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-XJFKSLPYSA-N 0.000 description 7
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 7
- 230000004156 Wnt signaling pathway Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 102000004041 Caspase 7 Human genes 0.000 description 5
- 108090000567 Caspase 7 Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 210000002242 Embryoid Bodies Anatomy 0.000 description 5
- 210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 210000002235 Sarcomeres Anatomy 0.000 description 4
- 101700004528 arp Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000006144 Dulbeccoâs modiï¬ed Eagle's medium Substances 0.000 description 3
- 210000004379 Membranes Anatomy 0.000 description 3
- RFSMUFRPPYDYRD-CALCHBBNSA-N [5-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-4-morpholin-4-ylpyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3C[C@@H](C)O[C@@H](C)C3)N3CCOCC3)C2=N1 RFSMUFRPPYDYRD-CALCHBBNSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101700005069 BMP4 Proteins 0.000 description 2
- 102100015886 BMP4 Human genes 0.000 description 2
- 102100017586 CACNA1H Human genes 0.000 description 2
- 108060001072 CACNA1H Proteins 0.000 description 2
- 208000005846 Cardiomyopathy Diseases 0.000 description 2
- 102100015284 DKK1 Human genes 0.000 description 2
- 101700029587 DKK1 Proteins 0.000 description 2
- 210000001900 Endoderm Anatomy 0.000 description 2
- 102100019094 HCN4 Human genes 0.000 description 2
- 101700006717 HCN4 Proteins 0.000 description 2
- 102000014021 KCNQ1 Potassium Channel Human genes 0.000 description 2
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108060001084 Luciferase family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 2
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 2
- 210000003470 Mitochondria Anatomy 0.000 description 2
- 210000004165 Myocardium Anatomy 0.000 description 2
- 101710012882 NKX2-5 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Resveratrol Natural products C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100017449 SCN5A Human genes 0.000 description 2
- 101700070146 SCN5A Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101700071614 WNT3A Proteins 0.000 description 2
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000002438 mitochondrial Effects 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methyls Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- KGAGDPCLSPRTNF-RGCQKQKKSA-N (6aS,11bR)-7,11b-dihydro-6H-indeno[2,1-c]chromene-3,4,6a,9,10-pentol;2',4',5',7'-tetrabromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2.O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 KGAGDPCLSPRTNF-RGCQKQKKSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- DUQTXODYOYERFR-UHFFFAOYSA-N 3-hydroxypyridine-2-carboxylic acid;oxido(oxo)vanadium Chemical compound [O-][V]=O.OC(=O)C1=NC=CC=C1O.OC(=O)C1=NC=CC=C1O DUQTXODYOYERFR-UHFFFAOYSA-N 0.000 description 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
- DDLZLOKCJHBUHD-WAVHTBQISA-N 6-bromoindirubin-3'-oxime Chemical compound O=C/1NC2=CC(Br)=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 DDLZLOKCJHBUHD-WAVHTBQISA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- 101710025910 ACT1A Proteins 0.000 description 1
- 101710038825 ATPK1 Proteins 0.000 description 1
- JXSVIVRDWWRQRT-GWXVJUCFSA-N Asiatic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C)[C@@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 JXSVIVRDWWRQRT-GWXVJUCFSA-N 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000000720 Eyelashes Anatomy 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 210000000887 Face Anatomy 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 108009000142 Heart Development Proteins 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000003632 Microfilaments Anatomy 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 206010028593 Myocardial disease Diseases 0.000 description 1
- 210000003365 Myofibrils Anatomy 0.000 description 1
- 108091005959 Myofilaments Proteins 0.000 description 1
- DOBKQCZBPPCLEG-UHFFFAOYSA-N N-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- HAGVCKULCLQGRF-UHFFFAOYSA-N Pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710009878 RPS6KB1 Proteins 0.000 description 1
- 102100011601 RPS6KB1 Human genes 0.000 description 1
- 241001506137 Rapa Species 0.000 description 1
- 210000001567 Regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 230000036191 S Phase Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 210000000587 Skeletal Muscle Fibers Anatomy 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 210000003014 Totipotent Stem Cells Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 210000002993 Trophoblasts Anatomy 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 210000002444 Unipotent stem cell Anatomy 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000011105 Wnt3 Protein Human genes 0.000 description 1
- 108010062659 Wnt3 Protein Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- 210000002072 atrial myocyte Anatomy 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 102000015735 beta Catenin Human genes 0.000 description 1
- 108060000903 beta Catenin Proteins 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000012024 dehydrating agentsâ Substances 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 101710024098 eif4ebp3l Proteins 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 101710031403 febA Proteins 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000001832 mitochondrialike Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 108009000411 p38 MAPK Signaling Pathway Proteins 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Description
æè¡åé
æ¬çºæã¯ãçç©æè¡ã®åéã«é¢ããå ·äœçã«ãå¹ççã«ããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããããã®å°ååååç©çµæç©ã«é¢ããã
æ¬çºæã¯ãçç©æè¡ã®åéã«é¢ããå ·äœçã«ãå¹ççã«ããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããããã®å°ååååç©çµæç©ã«é¢ããã
èæ¯æè¡
å¿ççŸæ£ã¯çŸä»£ç€ŸäŒã§çºççãšèŽæ»çãæãé«ãé床ã®çŸæ£ã®äžã€ã§ãå¿çèè¡ãªã©ã®çŸæ£ã«ããå¿çæå·ã¯äžå¯éçãªçŽ°èæ»ã§ããŸã æå¹ãªæ²»çæ段ãæ¬ ããŠãããããèæ§å¹¹çŽ°èïŒESCïŒããã³äººå·¥å€èœæ§å¹¹çŽ°èïŒhiPSïŒïŒããå€èœæ§å¹¹çŽ°èãšç·ç§°ãããïŒãçºèŠãããŠä»¥æ¥ãããå€èœæ§å¹¹çŽ°èç±æ¥ã®å¿ç现èã¯å¿ççŸæ£æ²»çã®åéã§æ°ããåžæã«ãªã£ãŠããã现èæ²»ç以å€ã幹现èç±æ¥ã®å¿ç现èã¯å¿ççŸæ£ã®æ²»çæ§è¬ç©ã®éžå¥ãè¬ç©ã®å¿èç¹ç°çæ¯æ§ã®æ€åºãªã©ã®éèŠãªé¢ã«äœ¿çšããããšãã§ããã20幎éã§ãããå€èœæ§å¹¹çŽ°èã®å®æ¹åæ§ååããã³å¿çšã®åéã§é£èºçãªçºå±ãåŸããããåæã§ã¯å¿ç现èãåŸãäž»ãªæ¹æ³ã¯ãããèæ§å¹¹çŽ°èãããŠã¹å èå èèæ§çŽ°è(Mouse visceral endoderm-like cellãEND-2)ãšå ±å¹é€ããæ¹æ³ããŸãã¯èæ§äœ(Embryonic bodyãEB)ã«ããæ¹æ³ã«ãã£ãŠåŸãããããããã®èªå°æ¹æ³ã¯ãåç©ç±æ¥ã®è¡æž ãå¿ èŠãªã ãã§ã¯ãããååå¹çãäœäžããåéãéåžžã«äœãã2007幎ã«ãCharles Murryå®éšå®€ã¯å局现èååç³»ã確ç«ããRPMI1640ãšB27ãããªãåºç€åå液ã«å¿çååä¿é²ãµã€ãã«ã€ã³ã§ããã¢ã¯ããã³AãšBMP4ãæ·»å ããããšã«ãã£ãŠãããèæ§å¹¹çŽ°èç³»H7ã§ã¯30ïŒ ã®ååæçã«éããããããèæ§å¹¹çŽ°èç³»H9ã§ã¯5ïŒ ã ããšæºè¶³ã§ãããã®ã§ã¯ãªããåŸæã¯ãæé©åãçµãŠãããªãã¡ãåååæã§Wnt3aãå ¥ããããã«DKK1ãå ¥ããŠWntã·ã°ãã«çµè·¯ã®æŽ»æ§ã調ç¯ãïŒä¿é²åŸæå¶ïŒãååå¹çãããçšåºŠåäžãããç¹ã«H9ã§ã30ïŒ ã®ååæçã«éããã
å¿ççŸæ£ã¯çŸä»£ç€ŸäŒã§çºççãšèŽæ»çãæãé«ãé床ã®çŸæ£ã®äžã€ã§ãå¿çèè¡ãªã©ã®çŸæ£ã«ããå¿çæå·ã¯äžå¯éçãªçŽ°èæ»ã§ããŸã æå¹ãªæ²»çæ段ãæ¬ ããŠãããããèæ§å¹¹çŽ°èïŒESCïŒããã³äººå·¥å€èœæ§å¹¹çŽ°èïŒhiPSïŒïŒããå€èœæ§å¹¹çŽ°èãšç·ç§°ãããïŒãçºèŠãããŠä»¥æ¥ãããå€èœæ§å¹¹çŽ°èç±æ¥ã®å¿ç现èã¯å¿ççŸæ£æ²»çã®åéã§æ°ããåžæã«ãªã£ãŠããã现èæ²»ç以å€ã幹现èç±æ¥ã®å¿ç现èã¯å¿ççŸæ£ã®æ²»çæ§è¬ç©ã®éžå¥ãè¬ç©ã®å¿èç¹ç°çæ¯æ§ã®æ€åºãªã©ã®éèŠãªé¢ã«äœ¿çšããããšãã§ããã20幎éã§ãããå€èœæ§å¹¹çŽ°èã®å®æ¹åæ§ååããã³å¿çšã®åéã§é£èºçãªçºå±ãåŸããããåæã§ã¯å¿ç现èãåŸãäž»ãªæ¹æ³ã¯ãããèæ§å¹¹çŽ°èãããŠã¹å èå èèæ§çŽ°è(Mouse visceral endoderm-like cellãEND-2)ãšå ±å¹é€ããæ¹æ³ããŸãã¯èæ§äœ(Embryonic bodyãEB)ã«ããæ¹æ³ã«ãã£ãŠåŸãããããããã®èªå°æ¹æ³ã¯ãåç©ç±æ¥ã®è¡æž ãå¿ èŠãªã ãã§ã¯ãããååå¹çãäœäžããåéãéåžžã«äœãã2007幎ã«ãCharles Murryå®éšå®€ã¯å局现èååç³»ã確ç«ããRPMI1640ãšB27ãããªãåºç€åå液ã«å¿çååä¿é²ãµã€ãã«ã€ã³ã§ããã¢ã¯ããã³AãšBMP4ãæ·»å ããããšã«ãã£ãŠãããèæ§å¹¹çŽ°èç³»H7ã§ã¯30ïŒ ã®ååæçã«éããããããèæ§å¹¹çŽ°èç³»H9ã§ã¯5ïŒ ã ããšæºè¶³ã§ãããã®ã§ã¯ãªããåŸæã¯ãæé©åãçµãŠãããªãã¡ãåååæã§Wnt3aãå ¥ããããã«DKK1ãå ¥ããŠWntã·ã°ãã«çµè·¯ã®æŽ»æ§ã調ç¯ãïŒä¿é²åŸæå¶ïŒãååå¹çãããçšåºŠåäžãããç¹ã«H9ã§ã30ïŒ ã®ååæçã«éããã
é·å¹Žã®çºå±ãçµãŠãããèæ§å¹¹çŽ°èã®å¿çãžã®ååæ¹æ³ã¯ããã¶ãé²å±ããŠããããååå¹çã¯ãŸã åäžããäœå°ããããååã®å®å®æ§ããã³ç°ãªã现èç³»ã«ãããäžèŽæ§ãããã«åäžãããå¿
èŠããããããéèŠãªã®ã¯ååã®ã³ã¹ããšåéã®ãããªå€§èŠæš¡çç£ã«åœ±é¿ããèŠçŽ ããŸã æŽãªãæ¹åãå¿
èŠã§ããããšã§ããã
ãã®ãããæ¬åéã§ã¯ãå€§å¹ ã«å¿ç现èã®ååçãåäžãããããšãã§ããå°ååååç©ããã³ãã®æ¹æ³ã®éçºãåæãããŠããã
ãã®ãããæ¬åéã§ã¯ãå€§å¹ ã«å¿ç现èã®ååçãåäžãããããšãã§ããå°ååååç©ããã³ãã®æ¹æ³ã®éçºãåæãããŠããã
çºæã®æŠèŠ
æ¬çºæã®ç®çã¯ãå€§å¹ ã«å¿ç现èã®ååçãåäžãããããšãã§ããå°ååååç©ããã³ãã®æ¹æ³ãæäŸããããšã§ããã
æ¬çºæã®ç¬¬äžã®åŽé¢ã§ã¯ã
ïŒiïŒ mTORã·ã°ãã«çµè·¯æå¶å€ãšã
ïŒiiïŒ Wntçµè·¯ä¿é²å€ãšã
ïŒiiiïŒ ä»»æã«è¬åŠçã«èš±å®¹ãããæ äœãšã
ãšããæåãå«ãå°ååååç©çµæç©ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã¯ã
ïŒiïŒ mTORã·ã°ãã«çµè·¯æå¶å€ãšã
ïŒiiïŒ Wntçµè·¯ä¿é²å€ãšã
ãšããæåãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæåïŒiïŒãšæåïŒiiïŒã®ã¢ã«æ¯ã¯1ã5000ïŒ5000ã15000ã奜ãŸããã¯2ã500ïŒ10000ã12000ããã奜ãŸããã¯5ã100ïŒ10000ã12000ãæã奜ãŸããã¯8ã60ïŒ10000ã12000ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®çµæç©ã®äœ¿çšæ¿åºŠã¯ã
æåïŒiiïŒã®Wntçµè·¯ä¿é²å€ã®äœ¿çšæ¿åºŠã1ã40ÎŒMã奜ãŸããã¯5ã25ÎŒMããã奜ãŸããã¯10ã20ÎŒMã§ããã
æ¬çºæã®ç®çã¯ãå€§å¹ ã«å¿ç现èã®ååçãåäžãããããšãã§ããå°ååååç©ããã³ãã®æ¹æ³ãæäŸããããšã§ããã
æ¬çºæã®ç¬¬äžã®åŽé¢ã§ã¯ã
ïŒiïŒ mTORã·ã°ãã«çµè·¯æå¶å€ãšã
ïŒiiïŒ Wntçµè·¯ä¿é²å€ãšã
ïŒiiiïŒ ä»»æã«è¬åŠçã«èš±å®¹ãããæ äœãšã
ãšããæåãå«ãå°ååååç©çµæç©ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã¯ã
ïŒiïŒ mTORã·ã°ãã«çµè·¯æå¶å€ãšã
ïŒiiïŒ Wntçµè·¯ä¿é²å€ãšã
ãšããæåãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæåïŒiïŒãšæåïŒiiïŒã®ã¢ã«æ¯ã¯1ã5000ïŒ5000ã15000ã奜ãŸããã¯2ã500ïŒ10000ã12000ããã奜ãŸããã¯5ã100ïŒ10000ã12000ãæã奜ãŸããã¯8ã60ïŒ10000ã12000ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®çµæç©ã®äœ¿çšæ¿åºŠã¯ã
æåïŒiiïŒã®Wntçµè·¯ä¿é²å€ã®äœ¿çšæ¿åºŠã1ã40ÎŒMã奜ãŸããã¯5ã25ÎŒMããã奜ãŸããã¯10ã20ÎŒMã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®çµæç©ã®äœ¿çšæ¿åºŠã¯ã
æåïŒiïŒã®mTORã·ã°ãã«çµè·¯æå¶å€ã®äœ¿çšæ¿åºŠã1ã200nMã奜ãŸããã¯5ã100nMããã奜ãŸããã¯10ã50nMã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšmTORã·ã°ãã«çµè·¯æå¶å€ã¯ãã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšWntçµè·¯ä¿é²å€ã¯ãCHIR99021ãBIOããŸãã¯ãããã®çµã¿åãããå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã¯ãããã«ãã»ãã®å¿ç现èååä¿é²å€ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã»ãã®å¿ç现èååä¿é²å€ã¯ãAKTã·ã°ãã«çµè·¯æå¶å€ã§ããLY99021ãå«ãã
æåïŒiïŒã®mTORã·ã°ãã«çµè·¯æå¶å€ã®äœ¿çšæ¿åºŠã1ã200nMã奜ãŸããã¯5ã100nMããã奜ãŸããã¯10ã50nMã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšmTORã·ã°ãã«çµè·¯æå¶å€ã¯ãã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšWntçµè·¯ä¿é²å€ã¯ãCHIR99021ãBIOããŸãã¯ãããã®çµã¿åãããå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã¯ãããã«ãã»ãã®å¿ç现èååä¿é²å€ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã»ãã®å¿ç现èååä¿é²å€ã¯ãAKTã·ã°ãã«çµè·¯æå¶å€ã§ããLY99021ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã¯æ¶²ç¶çµæç©ã§ãåæåã®æå¹æ¿åºŠã¯ã
mTORã·ã°ãã«çµè·¯æå¶å€ã§ã¯ãã©ããã€ã·ã³(Rapamycin)ã¯1nMã0.2ÎŒMã奜ãŸããã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ããšãããªã ã¹(RAD001)ã¯1nMã0.2ÎŒMã奜ãŸããã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ãKU-0063794ã¯1nMã0.2ÎŒMã奜ãŸããã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ãAZD8055ã¯1nMã0.2ÎŒMã奜ãŸããã¯ã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ã
Wntçµè·¯ä¿é²å€ã§ã¯ãCHIR99021ã¯1ÎŒMã12ÎŒMã奜ãŸããã¯3ÎŒã12ÎŒMããã奜ãŸããã¯10ÎŒMã12ÎŒMã§ãBioã¯0.5ÎŒMã2ÎŒMããã奜ãŸããã¯1ÎŒMã2ÎŒMã§ããã
æ¬çºæã®ç¬¬äºã®åŽé¢ã§ã¯ãïŒiïŒå¹¹çŽ°èã®å¿ç现èãžã®ååãä¿é²ããããšã«ãããå°ååååç©çµæç©ã®äœ¿çšãæäŸããã
mTORã·ã°ãã«çµè·¯æå¶å€ã§ã¯ãã©ããã€ã·ã³(Rapamycin)ã¯1nMã0.2ÎŒMã奜ãŸããã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ããšãããªã ã¹(RAD001)ã¯1nMã0.2ÎŒMã奜ãŸããã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ãKU-0063794ã¯1nMã0.2ÎŒMã奜ãŸããã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ãAZD8055ã¯1nMã0.2ÎŒMã奜ãŸããã¯ã¯5nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ã
Wntçµè·¯ä¿é²å€ã§ã¯ãCHIR99021ã¯1ÎŒMã12ÎŒMã奜ãŸããã¯3ÎŒã12ÎŒMããã奜ãŸããã¯10ÎŒMã12ÎŒMã§ãBioã¯0.5ÎŒMã2ÎŒMããã奜ãŸããã¯1ÎŒMã2ÎŒMã§ããã
æ¬çºæã®ç¬¬äºã®åŽé¢ã§ã¯ãïŒiïŒå¹¹çŽ°èã®å¿ç现èãžã®ååãä¿é²ããããšã«ãããå°ååååç©çµæç©ã®äœ¿çšãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã¯ãããã«ãïŒiiïŒå¹¹çŽ°èã®å¢æ®ã¬ãã«ãåäžãããããšãããã³/ãŸãã¯ïŒiiiïŒå¹¹çŽ°èã®ã¢ãããŒã·ã¹ãæå¶ããããšã«äœ¿çšãããŠãããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¢æ®ã¬ãã«ã¯ã幹现èã®å¢æ®æ°ããã³å¹¹çŽ°èã®æŽ»æ§ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯äººå·¥å€èœæ§å¹¹çŽ°èãèæ§å¹¹çŽ°èããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯ãå šèœæ§å¹¹çŽ°èãå«ãŸãªãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯ãåºä¹³åç©ã奜ãŸããã¯ããã霧æ¯åç©ïŒããšãã°ããŠã¹ãã©ããïŒç±æ¥ã®ãã®ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯ããå€èœæ§å¹¹çŽ°èïŒhuman induced pluripotent stem cellsãhiPSCïŒã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¢æ®ã¬ãã«ã¯ã幹现èã®å¢æ®æ°ããã³å¹¹çŽ°èã®æŽ»æ§ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯äººå·¥å€èœæ§å¹¹çŽ°èãèæ§å¹¹çŽ°èããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯ãå šèœæ§å¹¹çŽ°èãå«ãŸãªãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯ãåºä¹³åç©ã奜ãŸããã¯ããã霧æ¯åç©ïŒããšãã°ããŠã¹ãã©ããïŒç±æ¥ã®ãã®ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èã¯ããå€èœæ§å¹¹çŽ°èïŒhuman induced pluripotent stem cellsãhiPSCïŒã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšäººå€èœæ§å¹¹çŽ°èã¯ç®èç¹ç¶èœçŽ°èã尿现èãæ«æ¢¢è¡çŽ°èããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
æ¬çºæã®ç¬¬äžã®åŽé¢ã§ã¯ãäœå€ã§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããæ¹æ³ã§ãã£ãŠã
ïŒaïŒïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãšãïŒiiïŒWntçµè·¯ä¿é²å€ãšãå«ããååèªå°ååç©ã®çµã¿åããã®ååšäžã«ãããŠãå¹é€ç³»ã§å¹¹çŽ°èç³»ãå¹é€ããããšã«ãã£ãŠãåèšã®å¿ç现èãåŸãå·¥çšã
ãå«ãæ¹æ³ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹é€ç³»ã§ã¯ãåèšæåïŒiïŒãšæåïŒiiïŒã®ã¢ã«æ¯ã¯1ã5000ïŒ5000ã15000ã奜ãŸããã¯2ã500ïŒ10000ã12000ããã奜ãŸããã¯5ã100ïŒ10000ã12000ãæã奜ãŸããã¯8ã60ïŒ10000ã12000ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èç³»ã¯å€èœæ§å¹¹çŽ°èç³»ãŸãã¯åèœæ§å¹¹çŽ°èãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå€èœæ§å¹¹çŽ°èç³»ã¯ããå€èœæ§å¹¹çŽ°èç³»ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èç³»ã¯èæ§å¹¹çŽ°èç³»ã§ããH9-cTnT-eGFPãH9ãH7ãããå€èœæ§å¹¹çŽ°èç³»ã§ããU-Q1ããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
æ¬çºæã®ç¬¬äžã®åŽé¢ã§ã¯ãäœå€ã§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããæ¹æ³ã§ãã£ãŠã
ïŒaïŒïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãšãïŒiiïŒWntçµè·¯ä¿é²å€ãšãå«ããååèªå°ååç©ã®çµã¿åããã®ååšäžã«ãããŠãå¹é€ç³»ã§å¹¹çŽ°èç³»ãå¹é€ããããšã«ãã£ãŠãåèšã®å¿ç现èãåŸãå·¥çšã
ãå«ãæ¹æ³ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹é€ç³»ã§ã¯ãåèšæåïŒiïŒãšæåïŒiiïŒã®ã¢ã«æ¯ã¯1ã5000ïŒ5000ã15000ã奜ãŸããã¯2ã500ïŒ10000ã12000ããã奜ãŸããã¯5ã100ïŒ10000ã12000ãæã奜ãŸããã¯8ã60ïŒ10000ã12000ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èç³»ã¯å€èœæ§å¹¹çŽ°èç³»ãŸãã¯åèœæ§å¹¹çŽ°èãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå€èœæ§å¹¹çŽ°èç³»ã¯ããå€èœæ§å¹¹çŽ°èç³»ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¹¹çŽ°èç³»ã¯èæ§å¹¹çŽ°èç³»ã§ããH9-cTnT-eGFPãH9ãH7ãããå€èœæ§å¹¹çŽ°èç³»ã§ããU-Q1ããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€ã¯å°ãªããšã10åã奜ãŸããã¯å°ãªããšã20åãããå°ãªããšã30ã40åç¶ä»£å¹é€ããããšã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãå èè圢æã®åæ段éïŒçŽ3æ¥ç®ãŸã§ïŒã§åèšã®ååèªå°ååç©ã®çµã¿åãããæ·»å ãããã€ç¶æããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®æ·»å ã¯ååŸã§ãåæã«ïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãšãïŒiiïŒWntçµè·¯ä¿é²å€ãšãæ·»å ããããšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®ãæ·»å ãã¯ïŒiiïŒWntçµè·¯ä¿é²å€ãšãæ·»å ããåŸã§ãïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãæ·»å ããããšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®ãæ·»å ãã¯åèšå¹é€ç³»ã§ãïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ã®æ¿åºŠã1ã200nMã奜ãŸããã¯5ã100nMããã奜ãŸããã¯10ã50nMã«ããã€/ãŸãã¯ïŒiiïŒWntçµè·¯ä¿é²å€ã®æ¿åºŠã1ã40ÎŒMã奜ãŸããã¯5ã25ÎŒMããã奜ãŸããã¯10ã20ÎŒMã«ãªãããã«ãããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãå èè圢æã®åæ段éïŒçŽ3æ¥ç®ãŸã§ïŒã§åèšã®ååèªå°ååç©ã®çµã¿åãããæ·»å ãããã€ç¶æããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®æ·»å ã¯ååŸã§ãåæã«ïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãšãïŒiiïŒWntçµè·¯ä¿é²å€ãšãæ·»å ããããšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®ãæ·»å ãã¯ïŒiiïŒWntçµè·¯ä¿é²å€ãšãæ·»å ããåŸã§ãïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãæ·»å ããããšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®ãæ·»å ãã¯åèšå¹é€ç³»ã§ãïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ã®æ¿åºŠã1ã200nMã奜ãŸããã¯5ã100nMããã奜ãŸããã¯10ã50nMã«ããã€/ãŸãã¯ïŒiiïŒWntçµè·¯ä¿é²å€ã®æ¿åºŠã1ã40ÎŒMã奜ãŸããã¯5ã25ÎŒMããã奜ãŸããã¯10ã20ÎŒMã«ãªãããã«ãããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæ¹æ³ã¯ã
ïŒiïŒå¿ç现èã®ååçã85ã99.9ïŒ ã奜ãŸããã¯90ã98.5ïŒ ãšé«ãããšã
ïŒiiïŒå¹é€ã®éçšã§ã0.5mLãããã®å¹é€æ¶²ã«105åã®å¹¹çŽ°èãæ¥çš®ãããšã24Ã105åã®å¿ç现èãçæããããšã
ãããªã矀ããéžã°ãã1ã€ãŸãã¯è€æ°ã®ç¹åŸŽãæããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæ¹æ³ã¯ãããã«ãïŒbïŒå·¥çšïŒaïŒã§åŸãããå¿ç现èãæ¿çž®ããŠç²Ÿè£œããå·¥çšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšç²Ÿè£œæ¡ä»¶ã¯ã
ïŒa1ïŒç²Ÿè£œå¹é€æ¶²ã¯ççŽ æºãåºæ¬çã«ãŸãã¯å šéšä¹³ç³ãããªãåºç€å¹å°ã§ããã€2ã15ïŒ ïŒw/wïŒã®çèå è¡æž ãè¿œå ãããã®ã§ããããšã
ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€æ¶²ã¯0.1mMã10mMïŒå¥œãŸããã¯0.5mMã5mMããã奜ãŸããã¯1mMã4mMïŒã®ä¹³ç³ãå«ã¿ããã€2ã15ïŒ ïŒw/wïŒã®çèå è¡æž ãè¿œå ããDMEM/F12å¹å°ã§ããã
ïŒiïŒå¿ç现èã®ååçã85ã99.9ïŒ ã奜ãŸããã¯90ã98.5ïŒ ãšé«ãããšã
ïŒiiïŒå¹é€ã®éçšã§ã0.5mLãããã®å¹é€æ¶²ã«105åã®å¹¹çŽ°èãæ¥çš®ãããšã24Ã105åã®å¿ç现èãçæããããšã
ãããªã矀ããéžã°ãã1ã€ãŸãã¯è€æ°ã®ç¹åŸŽãæããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæ¹æ³ã¯ãããã«ãïŒbïŒå·¥çšïŒaïŒã§åŸãããå¿ç现èãæ¿çž®ããŠç²Ÿè£œããå·¥çšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšç²Ÿè£œæ¡ä»¶ã¯ã
ïŒa1ïŒç²Ÿè£œå¹é€æ¶²ã¯ççŽ æºãåºæ¬çã«ãŸãã¯å šéšä¹³ç³ãããªãåºç€å¹å°ã§ããã€2ã15ïŒ ïŒw/wïŒã®çèå è¡æž ãè¿œå ãããã®ã§ããããšã
ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€æ¶²ã¯0.1mMã10mMïŒå¥œãŸããã¯0.5mMã5mMããã奜ãŸããã¯1mMã4mMïŒã®ä¹³ç³ãå«ã¿ããã€2ã15ïŒ ïŒw/wïŒã®çèå è¡æž ãè¿œå ããDMEM/F12å¹å°ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€æ¶²ã«ãããŠç³ãå«ãŸããªããŠïŒããªãã¡å¹é€æ¶²ã®ç·ééã«å¯ŸããŠãããŠç³ã®å«æéãâŠ0.05wtïŒ
ã§ããïŒã
ïŒa2ïŒå¹é€æéã¯5ã8æ¥ã奜ãŸããã¯7ã8æ¥ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠã粟補ã§åŸãããå¿ç现èã¯99.9ïŒ ã®çŽåºŠãæããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæ¹æ³ã¯æ²»ççãªãã®ããã³éæ²»ççãªãã®ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€ç³»ã§ã幹现èç³»ã®å¯åºŠã0.1ã10Ã105现è/mLã奜ãŸããã¯0.5ã2Ã105现è/mLã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€ç³»ã¯ãäœç©ã0.1ã1000mLã奜ãŸããã¯0.2ã100mLããã奜ãŸããã¯0.3ã10mLãæã奜ãŸããã¯0.4ã0.6mLã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®åŸãããå¿ç现èã®æ°M2ãšåèšå¹¹çŽ°èã®æ°M1ã®æ¯M2/M1ã8ã36ã奜ãŸããã¯12ã30ããã奜ãŸããã¯16ã28ã§ããã
æ¬çºæã®ç¬¬åã®åŽé¢ã§ã¯ãæ¬çºæã®ç¬¬äžã®åŽé¢ã«èšèŒã®æ¹æ³ã«ãã£ãŠè£œé ãããå¿ç现èãæäŸããã
ïŒa2ïŒå¹é€æéã¯5ã8æ¥ã奜ãŸããã¯7ã8æ¥ã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠã粟補ã§åŸãããå¿ç现èã¯99.9ïŒ ã®çŽåºŠãæããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšæ¹æ³ã¯æ²»ççãªãã®ããã³éæ²»ççãªãã®ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€ç³»ã§ã幹现èç³»ã®å¯åºŠã0.1ã10Ã105现è/mLã奜ãŸããã¯0.5ã2Ã105现è/mLã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¹é€ç³»ã¯ãäœç©ã0.1ã1000mLã奜ãŸããã¯0.2ã100mLããã奜ãŸããã¯0.3ã10mLãæã奜ãŸããã¯0.4ã0.6mLã§ããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®åŸãããå¿ç现èã®æ°M2ãšåèšå¹¹çŽ°èã®æ°M1ã®æ¯M2/M1ã8ã36ã奜ãŸããã¯12ã30ããã奜ãŸããã¯16ã28ã§ããã
æ¬çºæã®ç¬¬åã®åŽé¢ã§ã¯ãæ¬çºæã®ç¬¬äžã®åŽé¢ã«èšèŒã®æ¹æ³ã«ãã£ãŠè£œé ãããå¿ç现èãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¿ç现èã¯ã
ïŒiïŒå¿ç现èã®ç¹ç°çæ§é éºäŒåãé«åºŠã«çºçŸãããããšã
ïŒiiïŒã€ãªã³ãã£ãã«éºäŒåãé«åºŠã«çºçŸãããããšã
ãããªã矀ããéžã°ãã1ã€ãŸãã¯è€æ°ã®ç¹åŸŽãæããã
æ¬çºæã®ç¬¬äºã®åŽé¢ã§ã¯ãå¿ç现èã®ååãä¿é²ãããããã§ãã£ãŠãæ¬çºæã®ç¬¬äžã®åŽé¢ã«èšèŒã®å°ååååç©çµæç©ãå«ãããããæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšãããã¯ãããã«ãã»ãã®å¿ç现èååä¿é²å€ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã»ãã®å¿ç现èååä¿é²å€ã¯ãP38 MAPK ã·ã°ãã«çµè·¯ã®æå¶å€ã§ããSB203580ããã¿ãã³C(ã¢ã¹ã³ã«ãã³é žãAscorbic acid)ãå šãã©ã³ã¹ã¬ããã€ã³é ž(Retinoid acid) ãAKTã·ã°ãã«çµè·¯æå¶å€ã§ããLY99021ããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
æ¬çºæã®ç¬¬å ã®åŽé¢ã§ã¯ãæ¬çºæã®ç¬¬åã®åŽé¢ã«èšèŒã®å¿ç现èã®äœ¿çšã§ãã£ãŠãå¿èçŸæ£ãäºé²ããã³/ãŸãã¯æ²»çããè¬ç©çµæç©ã®è£œé ã«ããã䜿çšãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¿èçŸæ£ã¯ãèè¡æ§å¿äžå šãå¿çæ¢å¡ããŸãã¯ãããã®çµã¿åãããå«ãã
ïŒiïŒå¿ç现èã®ç¹ç°çæ§é éºäŒåãé«åºŠã«çºçŸãããããšã
ïŒiiïŒã€ãªã³ãã£ãã«éºäŒåãé«åºŠã«çºçŸãããããšã
ãããªã矀ããéžã°ãã1ã€ãŸãã¯è€æ°ã®ç¹åŸŽãæããã
æ¬çºæã®ç¬¬äºã®åŽé¢ã§ã¯ãå¿ç现èã®ååãä¿é²ãããããã§ãã£ãŠãæ¬çºæã®ç¬¬äžã®åŽé¢ã«èšèŒã®å°ååååç©çµæç©ãå«ãããããæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšãããã¯ãããã«ãã»ãã®å¿ç现èååä¿é²å€ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã»ãã®å¿ç现èååä¿é²å€ã¯ãP38 MAPK ã·ã°ãã«çµè·¯ã®æå¶å€ã§ããSB203580ããã¿ãã³C(ã¢ã¹ã³ã«ãã³é žãAscorbic acid)ãå šãã©ã³ã¹ã¬ããã€ã³é ž(Retinoid acid) ãAKTã·ã°ãã«çµè·¯æå¶å€ã§ããLY99021ããŸãã¯ãããã®çµã¿åãããããªã矀ããéžã°ããã
æ¬çºæã®ç¬¬å ã®åŽé¢ã§ã¯ãæ¬çºæã®ç¬¬åã®åŽé¢ã«èšèŒã®å¿ç现èã®äœ¿çšã§ãã£ãŠãå¿èçŸæ£ãäºé²ããã³/ãŸãã¯æ²»çããè¬ç©çµæç©ã®è£œé ã«ããã䜿çšãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®å¿èçŸæ£ã¯ãèè¡æ§å¿äžå šãå¿çæ¢å¡ããŸãã¯ãããã®çµã¿åãããå«ãã
æ¬çºæã®ç¬¬äžã®åŽé¢ã§ã¯ãæ¬çºæã®ç¬¬åã®åŽé¢ã«èšèŒã®å¿ç现èãå«ãçµæç©ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®çµæç©ã¯ãè¬ç©çµæç©ãé£åçµæç©ãå¥åº·é£åçµæç©ãå«ãã
æ¬çºæã®ç¬¬å «ã®åŽé¢ã§ã¯ãå¿èçŸæ£ãæ²»çããæ¹æ³ã§ãã£ãŠãå¿ èŠãªå¯Ÿè±¡ã«å®å šæå¹éã®æ¬çºæã®ç¬¬åã®åŽé¢ã«èšèŒã®å¿ç现èãããã³/ãŸãã¯æ¬çºæã®ç¬¬äžã®åŽé¢ã«èšèŒã®çµæç©ãæœçšããæ¹æ³ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®æœçšã¯å±éšæ³šå°ã«ããæœçšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¯Ÿè±¡ã¯ãããŸãã¯ãã以å€ã®åºä¹³åç©ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšãã以å€ã®åºä¹³åç©ã¯éœ§æ¯åç©ãããšãã°ããŠã¹ãã©ãããå«ãã
ãã¡ãããæ¬çºæã®ç¯å²å ã«ãããŠãæ¬çºæã®äžèšã®åæè¡ç¹åŸŽããã³äžèšïŒããšãã°å®æœäŸïŒã®å ·äœçã«èšè¿°ãããåæè¡ç¹åŸŽã¯äºãã«çµåããæ°ããããŸãã¯å¥œé©ãªæè¡æ¹æ¡ãæ§æã§ããããšãç解ããããçŽæ°ã«éãããããããããã§éäžèª¬æããªãã
å³é¢ã®èª¬æ
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®çµæç©ã¯ãè¬ç©çµæç©ãé£åçµæç©ãå¥åº·é£åçµæç©ãå«ãã
æ¬çºæã®ç¬¬å «ã®åŽé¢ã§ã¯ãå¿èçŸæ£ãæ²»çããæ¹æ³ã§ãã£ãŠãå¿ èŠãªå¯Ÿè±¡ã«å®å šæå¹éã®æ¬çºæã®ç¬¬åã®åŽé¢ã«èšèŒã®å¿ç现èãããã³/ãŸãã¯æ¬çºæã®ç¬¬äžã®åŽé¢ã«èšèŒã®çµæç©ãæœçšããæ¹æ³ãæäŸããã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšã®æœçšã¯å±éšæ³šå°ã«ããæœçšãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå¯Ÿè±¡ã¯ãããŸãã¯ãã以å€ã®åºä¹³åç©ãå«ãã
ããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšãã以å€ã®åºä¹³åç©ã¯éœ§æ¯åç©ãããšãã°ããŠã¹ãã©ãããå«ãã
ãã¡ãããæ¬çºæã®ç¯å²å ã«ãããŠãæ¬çºæã®äžèšã®åæè¡ç¹åŸŽããã³äžèšïŒããšãã°å®æœäŸïŒã®å ·äœçã«èšè¿°ãããåæè¡ç¹åŸŽã¯äºãã«çµåããæ°ããããŸãã¯å¥œé©ãªæè¡æ¹æ¡ãæ§æã§ããããšãç解ããããçŽæ°ã«éãããããããããã§éäžèª¬æããªãã
å³é¢ã®èª¬æ
å
·äœçãªå®æœåœ¢æ
æ¬çºæè ã¯å¹ åºãæ·±ãç 究ãã倧éã®ååç©ã®éžå¥ãè¡ã£ããšãããåããŠæå€ã«ãç¹å®ã®å°ååååç©ã®çµã¿åããã¯å¹ççã«å€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããããšãã§ããåæéžå¥åŸã®å¿ç现èã®ååçã86ïŒ ã«éããæé©ååŸã®å¿ç现èã®ååçã98.3ïŒ ãšé«ãããã€ä¹³ç³æ¿çž®ç²Ÿè£œåŸã®å¿ç现èã99.9ïŒ ãšé«ãçŽåºŠãæããããšãèŠåºããã
å®éšã§ã¯ãmTORã·ã°ãã«çµè·¯æå¶å€ãšWntçµè·¯ä¿é²å€ãšãã2çš®é¡ã®ååç©ãå€èœæ§å¹¹çŽ°èïŒããšãã°ããå€èœæ§å¹¹çŽ°èïŒã«äœµçšããå Žåãå€èœæ§å¹¹çŽ°èãååãããŠåŸãããå¿ç现èã®æç床ãé«ããæ£åžžã®å¿çæ©èœãçºæ®ããæ§é ã®åºç€ãæããããªãã¡ãé¡äŒŒã®å¿çã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒåã®çºçŸã¬ãã«ãæããããããŠãæ¬çºæã®å¿çååãä¿é²ããæ¹æ³ã¯ãååã®å¹é€æ¶²ããã³æ·»å å€ãç¯çŽããã³ã¹ããå€§å¹ ã«äœäžãããããšãã§ãããããã«åºã¥ããçºæè ããæ¬çºæãå®æããã
æ¬çºæè ã¯å¹ åºãæ·±ãç 究ãã倧éã®ååç©ã®éžå¥ãè¡ã£ããšãããåããŠæå€ã«ãç¹å®ã®å°ååååç©ã®çµã¿åããã¯å¹ççã«å€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããããšãã§ããåæéžå¥åŸã®å¿ç现èã®ååçã86ïŒ ã«éããæé©ååŸã®å¿ç现èã®ååçã98.3ïŒ ãšé«ãããã€ä¹³ç³æ¿çž®ç²Ÿè£œåŸã®å¿ç现èã99.9ïŒ ãšé«ãçŽåºŠãæããããšãèŠåºããã
å®éšã§ã¯ãmTORã·ã°ãã«çµè·¯æå¶å€ãšWntçµè·¯ä¿é²å€ãšãã2çš®é¡ã®ååç©ãå€èœæ§å¹¹çŽ°èïŒããšãã°ããå€èœæ§å¹¹çŽ°èïŒã«äœµçšããå Žåãå€èœæ§å¹¹çŽ°èãååãããŠåŸãããå¿ç现èã®æç床ãé«ããæ£åžžã®å¿çæ©èœãçºæ®ããæ§é ã®åºç€ãæããããªãã¡ãé¡äŒŒã®å¿çã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒåã®çºçŸã¬ãã«ãæããããããŠãæ¬çºæã®å¿çååãä¿é²ããæ¹æ³ã¯ãååã®å¹é€æ¶²ããã³æ·»å å€ãç¯çŽããã³ã¹ããå€§å¹ ã«äœäžãããããšãã§ãããããã«åºã¥ããçºæè ããæ¬çºæãå®æããã
mTORã·ã°ãã«çµè·¯æå¶å€
mTORã¯ã»ãªã³ã»ã¹ã¬ãªãã³ãããã€ã³ãããŒãŒã§ã調ç¯ããæåã«ãã£ãŠãmTORC1ãšmTORC2ãšãã£ã2ã€ã®è€åäœã«åããããmTORC1ã¯äž»ã«ãªããœãŒã ã¿ã³ãã¯è³ªS6ãããŒãŒ1(S6K1ãŸãã¯p70s6K1)ã®ãªã³é žåã«ãã掻æ§åããã³4E-çµåã¿ã³ãã¯è³ª(4E-BP)ã®ãªã³é žåã«ããæå¶ã«ãã£ãŠçŽ°èå ã«ãããã¿ã³ãã¯è³ªåæã®é床ã調ç¯ããã
mTORã·ã°ãã«çµè·¯æå¶å€ã¯ãéåžžãã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ãªã©ãå«ãã
æ¬çºæã«ãããŠãã©ããã€ã·ã³ããšãããªã ã¹ïŒEverolimus/RAD001ïŒãKU-0063794ïŒGarcia-Martinez JMããBiochem J. 2009ã421(1):29-42ïŒãAZD8055ïŒChresta CMããCancer Resã2010ã70(1)ã288-298.ïŒãªã©ã®mTORã·ã°ãã«çµè·¯æå¶å€ã®å¿ç现èã®ååã«å¯Ÿããå¹æãæ€åºããã
mTORã¯ã»ãªã³ã»ã¹ã¬ãªãã³ãããã€ã³ãããŒãŒã§ã調ç¯ããæåã«ãã£ãŠãmTORC1ãšmTORC2ãšãã£ã2ã€ã®è€åäœã«åããããmTORC1ã¯äž»ã«ãªããœãŒã ã¿ã³ãã¯è³ªS6ãããŒãŒ1(S6K1ãŸãã¯p70s6K1)ã®ãªã³é žåã«ãã掻æ§åããã³4E-çµåã¿ã³ãã¯è³ª(4E-BP)ã®ãªã³é žåã«ããæå¶ã«ãã£ãŠçŽ°èå ã«ãããã¿ã³ãã¯è³ªåæã®é床ã調ç¯ããã
mTORã·ã°ãã«çµè·¯æå¶å€ã¯ãéåžžãã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ãªã©ãå«ãã
æ¬çºæã«ãããŠãã©ããã€ã·ã³ããšãããªã ã¹ïŒEverolimus/RAD001ïŒãKU-0063794ïŒGarcia-Martinez JMããBiochem J. 2009ã421(1):29-42ïŒãAZD8055ïŒChresta CMããCancer Resã2010ã70(1)ã288-298.ïŒãªã©ã®mTORã·ã°ãã«çµè·¯æå¶å€ã®å¿ç现èã®ååã«å¯Ÿããå¹æãæ€åºããã
Wntçµè·¯ä¿é²å€
Wntã·ã°ãã«çµè·¯ã¯æ¢ç¥ã®å¿èçºè²ã調ç¯ããæãéèŠãªã·ã°ãã«çµè·¯ã§ãããWntã¿ã³ãã¯è³ªãããšãã°Wnt3ã¯åæ³åç³ã¿ã³ãã¯è³ªã«å±ããååæ³ãŸãã¯èªå·±åæ³äœçšã«ãã£ãŠçŽ°èèã«ããå容äœãšçµåãã现èå ã«ãããå段éã®ã·ã°ãã«äŒéååãäž»ã«Î²-ã«ããã³ã®æ žå ãžã®ç§»è¡ã掻æ§åããæšçéºäŒåã®çºçŸã調ç¯ãããWntçµè·¯ä¿é²å€ã¯ãéåžžãCHIR99021ããã³BIOãå«ãã
æ¬çºæã«ãããŠãCHIR99021ïŒBennett CNããJ Biol Chemã2002,277(34),30998-31004.ïŒãBioïŒ6-ããã¢ã€ã³ãžã«ãã³-3'-ãªãã·ã ïŒ6-bromoindirubin-3'-oximeïŒïŒãšãã£ã2ã€ã®Wntçµè·¯ä¿é²å€ã®å¿ç现èã®ååã«å¯Ÿãã圱é¿ãæ€åºããã
Wntã·ã°ãã«çµè·¯ã¯æ¢ç¥ã®å¿èçºè²ã調ç¯ããæãéèŠãªã·ã°ãã«çµè·¯ã§ãããWntã¿ã³ãã¯è³ªãããšãã°Wnt3ã¯åæ³åç³ã¿ã³ãã¯è³ªã«å±ããååæ³ãŸãã¯èªå·±åæ³äœçšã«ãã£ãŠçŽ°èèã«ããå容äœãšçµåãã现èå ã«ãããå段éã®ã·ã°ãã«äŒéååãäž»ã«Î²-ã«ããã³ã®æ žå ãžã®ç§»è¡ã掻æ§åããæšçéºäŒåã®çºçŸã調ç¯ãããWntçµè·¯ä¿é²å€ã¯ãéåžžãCHIR99021ããã³BIOãå«ãã
æ¬çºæã«ãããŠãCHIR99021ïŒBennett CNããJ Biol Chemã2002,277(34),30998-31004.ïŒãBioïŒ6-ããã¢ã€ã³ãžã«ãã³-3'-ãªãã·ã ïŒ6-bromoindirubin-3'-oximeïŒïŒãšãã£ã2ã€ã®Wntçµè·¯ä¿é²å€ã®å¿ç现èã®ååã«å¯Ÿãã圱é¿ãæ€åºããã
å°ååååç©çµæç©
æ¬æ现æžã§çšããããããã«ãçšèªãå°ååååç©çµæç©ããšã¯ïŒiïŒ mTORã·ã°ãã«çµè·¯æå¶å€ãããã³ïŒiiïŒ Wntçµè·¯ä¿é²å€ãšããæåãå«ãçµæç©ãããããŸããåèšã®å°ååååç©çµæç©ã¯è¬åŠçã«èš±å®¹ãããæ äœãå«ãã§ããããããã®ãããªå Žåãåèšã®å°ååååç©çµæç©ã¯å€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ãã掻æ§ãæããè¬ç©çµæç©ã«ãªãã
ããã§ãåèšã®mTORã·ã°ãã«çµè·¯æå¶å€ã¯ãéåžžãã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ãå«ãã
åèšWntçµè·¯ä¿é²å€ã¯ãCHIR99021ãBIOããŸãã¯ãããã®çµã¿åãããå«ãã
æ¬çºæã®å°ååçµæç©ã«äœ¿çšã§ããåæåã®éã®æ¯çã«ã¯äœãã®å¶éããªããéåžžãåæåã¯ãã®æäœã®æå¹æ¿åºŠãæºè¶³ãããªããã°ãªããªããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã«ãããåæåã®æäœæå¹æ¿åºŠã¯ä»¥äžã®éãã§ããã
æ¬æ现æžã§çšããããããã«ãçšèªãå°ååååç©çµæç©ããšã¯ïŒiïŒ mTORã·ã°ãã«çµè·¯æå¶å€ãããã³ïŒiiïŒ Wntçµè·¯ä¿é²å€ãšããæåãå«ãçµæç©ãããããŸããåèšã®å°ååååç©çµæç©ã¯è¬åŠçã«èš±å®¹ãããæ äœãå«ãã§ããããããã®ãããªå Žåãåèšã®å°ååååç©çµæç©ã¯å€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ãã掻æ§ãæããè¬ç©çµæç©ã«ãªãã
ããã§ãåèšã®mTORã·ã°ãã«çµè·¯æå¶å€ã¯ãéåžžãã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ãå«ãã
åèšWntçµè·¯ä¿é²å€ã¯ãCHIR99021ãBIOããŸãã¯ãããã®çµã¿åãããå«ãã
æ¬çºæã®å°ååçµæç©ã«äœ¿çšã§ããåæåã®éã®æ¯çã«ã¯äœãã®å¶éããªããéåžžãåæåã¯ãã®æäœã®æå¹æ¿åºŠãæºè¶³ãããªããã°ãªããªããäžã€ã®å¥œé©ãªäŸã«ãããŠãåèšå°ååååç©çµæç©ã«ãããåæåã®æäœæå¹æ¿åºŠã¯ä»¥äžã®éãã§ããã
mTORã·ã°ãã«çµè·¯æå¶å€ã§ã¯ãã©ããã€ã·ã³(Rapamycin)ã¯1nMã0.2ÎŒMã奜ãŸããã¯1nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ããšãããªã ã¹(RAD001)ã¯1nMã0.2ÎŒMã奜ãŸããã¯1nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ãKU-0063794ã¯1nMã0.2ÎŒMã奜ãŸããã¯1nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ãAZD8055ã¯1nMã0.2ÎŒMã奜ãŸããã¯ã¯1nMã0.1ÎŒMããã奜ãŸããã¯10nMã50nMã§ã
Wntçµè·¯ä¿é²å€ã§ã¯ãCHIR99021ã¯1ÎŒMã12ÎŒMã奜ãŸããã¯3ÎŒã12ÎŒMããã奜ãŸããã¯10ÎŒMã12ÎŒMã§ãBioã¯0.5ÎŒMã2ÎŒMããã奜ãŸããã¯1ÎŒMã2ÎŒMã§ããã
æ¬çºæã«ãããŠãã©ããã€ã·ã³(Rapamycin)ãšCHIR99021ã®çµã¿åããã¯åªãã人工å€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ãã掻æ§ãæããããšãæ€èšŒãããããã¡ãããåœæ¥è ã¯æ¬çºæã®å瀺ãåãã以äžã®2çš®é¡ã®é»å®³å€ãä»»æã«çµã¿åãããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ãã掻æ§ãæããå°ååååç©çµæç©ãéçºããããšãã§ããã
æ¬æ现æžã«çšããããããã«ãçšèªãããå€èœæ§å¹¹çŽ°èãããå€èœæ§å¹¹çŽ°èãããhiPSCãã¯å ¥ãæ¿ããŠäœ¿çšããããšãã§ããããããããç±æ¥ã®åé¢ãããå€èœæ§å¹¹çŽ°èããããæ¬çºæã«ãããŠãæ¬çºæã®hiPSCã¯ããè äžç®çŽ°èç±æ¥ã®ãã®ã§ãããã
Wntçµè·¯ä¿é²å€ã§ã¯ãCHIR99021ã¯1ÎŒMã12ÎŒMã奜ãŸããã¯3ÎŒã12ÎŒMããã奜ãŸããã¯10ÎŒMã12ÎŒMã§ãBioã¯0.5ÎŒMã2ÎŒMããã奜ãŸããã¯1ÎŒMã2ÎŒMã§ããã
æ¬çºæã«ãããŠãã©ããã€ã·ã³(Rapamycin)ãšCHIR99021ã®çµã¿åããã¯åªãã人工å€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ãã掻æ§ãæããããšãæ€èšŒãããããã¡ãããåœæ¥è ã¯æ¬çºæã®å瀺ãåãã以äžã®2çš®é¡ã®é»å®³å€ãä»»æã«çµã¿åãããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ãã掻æ§ãæããå°ååååç©çµæç©ãéçºããããšãã§ããã
æ¬æ现æžã«çšããããããã«ãçšèªãããå€èœæ§å¹¹çŽ°èãããå€èœæ§å¹¹çŽ°èãããhiPSCãã¯å ¥ãæ¿ããŠäœ¿çšããããšãã§ããããããããç±æ¥ã®åé¢ãããå€èœæ§å¹¹çŽ°èããããæ¬çºæã«ãããŠãæ¬çºæã®hiPSCã¯ããè äžç®çŽ°èç±æ¥ã®ãã®ã§ãããã
å¿ç现è
å¿ç现èïŒCardiomyocyteïŒã¯æçå¿ç现èã®åºæ¬ç¹åŸŽãæããçç·ç¶ããµã«ã³ã¡ã¢ã现èéé£çµ¡ïŒä»åšæ¿ïŒãæçããã³ã³ããªã¢ãå¿çç¹ç°çã€ãªã³ãã£ãã«ãå«ãã
æ¬çºæã«ãããŠãããå€èœæ§å¹¹çŽ°èã¯æ¬çºæã®å°ååååç©çµæç©ïŒè¬ç©çµæç©ïŒã«ãã£ãŠèªå°ãããŠå¿ç现èã«ååããååããŠåŸãããå¿ç现èã¯ããã«å¿å®€ç现èãå¿æ¿ç现èããã³ããŒã¹ã¡ãŒã«ãŒãšãã£ã3ã€ã®çŽ°èã®ãµãã¿ã€ãã«åãããã
å¿ç现èïŒCardiomyocyteïŒã¯æçå¿ç现èã®åºæ¬ç¹åŸŽãæããçç·ç¶ããµã«ã³ã¡ã¢ã现èéé£çµ¡ïŒä»åšæ¿ïŒãæçããã³ã³ããªã¢ãå¿çç¹ç°çã€ãªã³ãã£ãã«ãå«ãã
æ¬çºæã«ãããŠãããå€èœæ§å¹¹çŽ°èã¯æ¬çºæã®å°ååååç©çµæç©ïŒè¬ç©çµæç©ïŒã«ãã£ãŠèªå°ãããŠå¿ç现èã«ååããååããŠåŸãããå¿ç现èã¯ããã«å¿å®€ç现èãå¿æ¿ç现èããã³ããŒã¹ã¡ãŒã«ãŒãšãã£ã3ã€ã®çŽ°èã®ãµãã¿ã€ãã«åãããã
å¿ç现èã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒå
æ¬æ现æžã«çšããããããã«ãçšèªãå¿ç现èã®ç¹ç°çæ§é éºäŒåããšãã€ãªã³ãã£ãã«éºäŒåããšã¯éå¿ç现èãšæ¯ã¹ãå¿ç现èã§é«åºŠã«çºçŸãããéºäŒåïŒãŸãã¯ãã®ã¿ã³ãã¯è³ªïŒããããéåžžãåèšã®å¿ç现èã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒåã¯ãcTnTãαMHCã Nkx2.5ãHCN4ãNav1.5ãCav3.2ãKCNQ1ãªã©ãå«ãã
æ¬æ现æžã«çšããããããã«ãçšèªãå¿ç现èã®ç¹ç°çæ§é éºäŒåããšãã€ãªã³ãã£ãã«éºäŒåããšã¯éå¿ç现èãšæ¯ã¹ãå¿ç现èã§é«åºŠã«çºçŸãããéºäŒåïŒãŸãã¯ãã®ã¿ã³ãã¯è³ªïŒããããéåžžãåèšã®å¿ç现èã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒåã¯ãcTnTãαMHCã Nkx2.5ãHCN4ãNav1.5ãCav3.2ãKCNQ1ãªã©ãå«ãã
èªå°æ¹æ³
æ¬çºæã®å€èœæ§å¹¹çŽ°èïŒããšãã°ããå€èœæ§å¹¹çŽ°èïŒã®å¿ç现èãžã®ååãèªå°ããæ¹æ³ã¯ãéåžžãäœå€ã«ãããèªå°æ¹æ³ããããããã¡ãããäœå€èªå°å®éšãåç §ããŠãããªãäœå èªå°ãè¡ã£ãŠããããããã¯æ¬åéã®éåžžã®æè¡ãŸãã¯æ¹æ³ãåç §ããŠç 究ããããšã«ãã£ãŠåŸãããšãã§ããã
éåžžãæ¬çºæã®å°ååååç©çµæç©ãååšããæ¡ä»¶ã«ãããŠãå€èœæ§å¹¹çŽ°èãå¹é€ããã
ãŸããæ¬åéã®éåžžã®å¿ç现èå¹å°ã§åèšã®å€èœæ§å¹¹çŽ°èïŒããšãã°ããå€èœæ§å¹¹çŽ°èïŒã«å¯ŸããŠãããªãå¹é€ãè¡ã£ãŠãããã奜ãŸããã¯ãåèšã®å¿ç现èå¹å°ã«Wntã·ã°ãã«çµè·¯ã®ä¿é²å€ã§ããCHIR99021ãmTORã·ã°ãã«çµè·¯ã®æå¶å€ã§ããã©ããã€ã·ã³ããŸãã¯ãããã®çµã¿åãããå«æãããŠãããã
äžã€ã®å¥œé©ãªå®æœåœ¢æ ã«ãããŠãæ¬çºæã®èªå°æ¹æ³ã¯ããã«å¿ç现èã®æ¿çž®ç²Ÿè£œãå«ãã
æ¬çºæã®å€èœæ§å¹¹çŽ°èïŒããšãã°ããå€èœæ§å¹¹çŽ°èïŒã®å¿ç现èãžã®ååãèªå°ããæ¹æ³ã¯ãéåžžãäœå€ã«ãããèªå°æ¹æ³ããããããã¡ãããäœå€èªå°å®éšãåç §ããŠãããªãäœå èªå°ãè¡ã£ãŠããããããã¯æ¬åéã®éåžžã®æè¡ãŸãã¯æ¹æ³ãåç §ããŠç 究ããããšã«ãã£ãŠåŸãããšãã§ããã
éåžžãæ¬çºæã®å°ååååç©çµæç©ãååšããæ¡ä»¶ã«ãããŠãå€èœæ§å¹¹çŽ°èãå¹é€ããã
ãŸããæ¬åéã®éåžžã®å¿ç现èå¹å°ã§åèšã®å€èœæ§å¹¹çŽ°èïŒããšãã°ããå€èœæ§å¹¹çŽ°èïŒã«å¯ŸããŠãããªãå¹é€ãè¡ã£ãŠãããã奜ãŸããã¯ãåèšã®å¿ç现èå¹å°ã«Wntã·ã°ãã«çµè·¯ã®ä¿é²å€ã§ããCHIR99021ãmTORã·ã°ãã«çµè·¯ã®æå¶å€ã§ããã©ããã€ã·ã³ããŸãã¯ãããã®çµã¿åãããå«æãããŠãããã
äžã€ã®å¥œé©ãªå®æœåœ¢æ ã«ãããŠãæ¬çºæã®èªå°æ¹æ³ã¯ããã«å¿ç现èã®æ¿çž®ç²Ÿè£œãå«ãã
è¬ç©çµæç©
æ¬çºæã¯æ¬çºæã«èšèŒã®å¿ç现èãå«ãçµæç©ãæäŸããã
奜ãŸããã¯ãåèšã®çµæç©ã¯ãè¬ç©çµæç©ãé£åçµæç©ãå¥åº·é£åçµæç©ãªã©ã§ããã
æ¬çºæã®è¬ç©çµæç©ã¯ãè¬åŠçã«èš±å®¹ãããæ äœãšãæå¹éã®æŽ»æ§æåãããªãã¡ãæ¬çºæã«èšèŒã®å¿ç现èãšãå«ãã
æ¬æ现æžã§çšããããããã«ãçšèªãæå¹éããŸãã¯ãæå¹æäžéããšã¯ãããããã³/ãŸãã¯åç©ã«æ©èœã掻æ§ãããããã€ããããã³/ãŸãã¯åç©ã«ãšã£ãŠåããããéã§ããã
æ¬æ现æžã§çšããããããã«ããè¬åŠçã«èš±å®¹ãããæ äœãã®æåã¯ãããããã³/ãŸãã¯åºä¹³åç©ã«é©çšããå Žåãé床ã®äžè¯ãªå¯åå¿ïŒããšãã°æ¯æ§ãåºæ¿ãšã¢ã¬ã«ã®ãŒåå¿ïŒããªããããªãã¡ãåççãªãããã£ãã/ãªã¹ã¯æ¯ãæã€ç©è³ªã§ãããçšèªãè¬åŠçã«èš±å®¹ãããæ äœããšã¯ãæ²»çå€ã®çµŠäžã®ããã®æ äœã§ãæ§ã ãªè³Šåœ¢å€ãšåžéå€ãå«ãã
æ¬çºæã¯æ¬çºæã«èšèŒã®å¿ç现èãå«ãçµæç©ãæäŸããã
奜ãŸããã¯ãåèšã®çµæç©ã¯ãè¬ç©çµæç©ãé£åçµæç©ãå¥åº·é£åçµæç©ãªã©ã§ããã
æ¬çºæã®è¬ç©çµæç©ã¯ãè¬åŠçã«èš±å®¹ãããæ äœãšãæå¹éã®æŽ»æ§æåãããªãã¡ãæ¬çºæã«èšèŒã®å¿ç现èãšãå«ãã
æ¬æ现æžã§çšããããããã«ãçšèªãæå¹éããŸãã¯ãæå¹æäžéããšã¯ãããããã³/ãŸãã¯åç©ã«æ©èœã掻æ§ãããããã€ããããã³/ãŸãã¯åç©ã«ãšã£ãŠåããããéã§ããã
æ¬æ现æžã§çšããããããã«ããè¬åŠçã«èš±å®¹ãããæ äœãã®æåã¯ãããããã³/ãŸãã¯åºä¹³åç©ã«é©çšããå Žåãé床ã®äžè¯ãªå¯åå¿ïŒããšãã°æ¯æ§ãåºæ¿ãšã¢ã¬ã«ã®ãŒåå¿ïŒããªããããªãã¡ãåççãªãããã£ãã/ãªã¹ã¯æ¯ãæã€ç©è³ªã§ãããçšèªãè¬åŠçã«èš±å®¹ãããæ äœããšã¯ãæ²»çå€ã®çµŠäžã®ããã®æ äœã§ãæ§ã ãªè³Šåœ¢å€ãšåžéå€ãå«ãã
æ¬çºæã®è¬ç©çµæç©ã¯ãå®å
šæå¹éã®æ¬çºæã®æŽ»æ§æåãšãè¬åŠçã«èš±å®¹ãããæ
äœãšãå«ãããã®ãããªæ
äœã¯ãé£å¡©æ°Žãç·©è¡æ¶²ããããŠç³ãæ°Žãã°ãªã»ãªã³ããšã¿ããŒã«ãããã³ãããã®çµã¿åããå«ããããããã«éå®ãããªããéåžžãè¬ç©è£œå€ã¯æäžæ§æ
ã«å¿ããæ¬çºæã®è¬ç©çµæç©ã®å€åœ¢ã¯ã泚å°å€ãçµå£æäžè£œå€ïŒé å€ãã«ãã»ã«ãçµå£æäžæ¶²ïŒãçµç®å€ãåŸæŸå€ã§ãããããšãã°ççé£å¡©æ°Žãããã¯ãããŠç³ããã³ã»ãã®å©å€ãå«ã氎溶液ã§éåžžã®æ¹æ³ã«ãã£ãŠè£œé ããããšãã§ãããåèšã®è¬ç©çµæç©ã¯ãç¡èæ¡ä»¶ã§è£œé ããããšã奜ãŸããã
æ¬çºæã«èšèŒã®æŽ»æ§æåã®æå¹éã¯ãæäžã®æ§æ ãšæ²»çããããšããçŸæ£ã®é節床ãªã©ã«ãã£ãŠå€æŽããããšãã§ããã奜é©ãªæå¹éã®éžæã¯ãåœæ¥è ããããããªèŠçŽ ã«ãã£ãŠæ±ºããããšãã§ããïŒããšãã°èšåºè©Šéšã«ããïŒãåèšã®èŠçŽ ã¯ãåèšã®æŽ»æ§æåã®è¬ç©åæ åŠã®ãã©ã¡ãŒã¿ãŒãããšãã°çç©å©çšèœã代è¬ãåæžæãªã©ãæ£è ã®æ²»çããããšããçŸæ£ã®é節床ãæ£è ã®äœéãæ£è ã®å ç«ç¶æ³ãæäžã®çµè·¯ãªã©ãå«ããããããã«éå®ãããªããéåžžãæ¬çºæã®æŽ»æ§æåã¯ãæ¯æ¥0.00001 mgã50 mg/kgåç©äœéïŒå¥œãŸããã¯0.0001 mgã10 mg/kgåç©äœéïŒã®æäžéã§æäžããå Žåãæºè¶³ã§ããå¹æãåŸããããããšãã°ãæ²»çç¶æ³ã®åæã«ãã£ãŠãæ¯æ¥æ°åã«åããæäžéããŸãã¯æ¯ççã«æžå°ããæäžéã§æäžããããšãã§ããã
æ¬çºæã«èšèŒã®è¬åŠçã«èš±å®¹ãããæ äœã¯ãæ°Žãå¡©æ°ŽããªããœãŒã ãè質ãã¿ã³ãã¯è³ªãã¿ã³ãã¯è³ª-æäœè€åäœãããããç³»ç©è³ªãã»ã«ããŒã¹ãããã²ã«ããŸãã¯ãããã®çµã¿åãããå«ããããããã«éå®ãããªããæ äœã®éžæã¯æäžæ§æ ã«å¿ãããããã¯ãã¹ãŠåœæ¥è ã«çç¥ã®ããšã§ããã
ãŸããæ¬çºæã¯ãå¿èçŸæ£ã®äºé²ããã³/ãŸãã¯æ²»çã«ãããåèšè¬ç©çµæç©ã®äœ¿çšãæäŸããã
æ¬çºæã«èšèŒã®æŽ»æ§æåã®æå¹éã¯ãæäžã®æ§æ ãšæ²»çããããšããçŸæ£ã®é節床ãªã©ã«ãã£ãŠå€æŽããããšãã§ããã奜é©ãªæå¹éã®éžæã¯ãåœæ¥è ããããããªèŠçŽ ã«ãã£ãŠæ±ºããããšãã§ããïŒããšãã°èšåºè©Šéšã«ããïŒãåèšã®èŠçŽ ã¯ãåèšã®æŽ»æ§æåã®è¬ç©åæ åŠã®ãã©ã¡ãŒã¿ãŒãããšãã°çç©å©çšèœã代è¬ãåæžæãªã©ãæ£è ã®æ²»çããããšããçŸæ£ã®é節床ãæ£è ã®äœéãæ£è ã®å ç«ç¶æ³ãæäžã®çµè·¯ãªã©ãå«ããããããã«éå®ãããªããéåžžãæ¬çºæã®æŽ»æ§æåã¯ãæ¯æ¥0.00001 mgã50 mg/kgåç©äœéïŒå¥œãŸããã¯0.0001 mgã10 mg/kgåç©äœéïŒã®æäžéã§æäžããå Žåãæºè¶³ã§ããå¹æãåŸããããããšãã°ãæ²»çç¶æ³ã®åæã«ãã£ãŠãæ¯æ¥æ°åã«åããæäžéããŸãã¯æ¯ççã«æžå°ããæäžéã§æäžããããšãã§ããã
æ¬çºæã«èšèŒã®è¬åŠçã«èš±å®¹ãããæ äœã¯ãæ°Žãå¡©æ°ŽããªããœãŒã ãè質ãã¿ã³ãã¯è³ªãã¿ã³ãã¯è³ª-æäœè€åäœãããããç³»ç©è³ªãã»ã«ããŒã¹ãããã²ã«ããŸãã¯ãããã®çµã¿åãããå«ããããããã«éå®ãããªããæ äœã®éžæã¯æäžæ§æ ã«å¿ãããããã¯ãã¹ãŠåœæ¥è ã«çç¥ã®ããšã§ããã
ãŸããæ¬çºæã¯ãå¿èçŸæ£ã®äºé²ããã³/ãŸãã¯æ²»çã«ãããåèšè¬ç©çµæç©ã®äœ¿çšãæäŸããã
æ¬çºæã®äž»ãªå©ç¹ã¯ä»¥äžã®éãã§ããã
ïŒ1ïŒæ¬çºæã®æ¹æ³ã¯ãç¹å®ã®ã·ã°ãã«çµè·¯ã®é»å®³å€ã®çµã¿åãããå©çšããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããååããŠåŸãããå¿ç现èã®æç床ãé«ããæ£åžžã®å¿çæ©èœãçºæ®ããæ§é ã®åºç€ãæããããªãã¡ãé¡äŒŒã®å¿çã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒåã®çºçŸã¬ãã«ãæããã
ïŒ2ïŒæ¬çºæã®å¿çååãä¿é²ããæ¹æ³ã¯ãååã®å¹é€æ¶²ããã³æ·»å å€ãç¯çŽããã³ã¹ããå€§å¹ ã«äœäžãããããšãã§ããã
ïŒ3ïŒæ¬åéã®å¿çååãä¿é²ããæ¹æ³ã¯ãé«ãå¿ç现èååçãæãã1åã®å¹¹çŽ°èãã24åã®å¿ç现èãçæããåæéžå¥åŸã®å¿ç现èã®ååçã86ïŒ ã«éããæé©ååŸã®å¿ç现èã®ååçã98.3ïŒ ãšé«ãïŒH7ããèæ§å¹¹çŽ°èç³»ïŒãå¿ç现èãæ¿çž®ç²Ÿè£œããŠåŸãããå¿ç现èã®çŽåºŠãããé«ãã99.9ïŒ ã«éããã
ãã®ãããæ¬çºæã¯é¢é£ãã现èæ²»çã«ããè¯ãçç¥ã®åè£ãæäŸããã
ïŒ1ïŒæ¬çºæã®æ¹æ³ã¯ãç¹å®ã®ã·ã°ãã«çµè·¯ã®é»å®³å€ã®çµã¿åãããå©çšããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããååããŠåŸãããå¿ç现èã®æç床ãé«ããæ£åžžã®å¿çæ©èœãçºæ®ããæ§é ã®åºç€ãæããããªãã¡ãé¡äŒŒã®å¿çã®ç¹ç°çæ§é éºäŒåãšã€ãªã³ãã£ãã«éºäŒåã®çºçŸã¬ãã«ãæããã
ïŒ2ïŒæ¬çºæã®å¿çååãä¿é²ããæ¹æ³ã¯ãååã®å¹é€æ¶²ããã³æ·»å å€ãç¯çŽããã³ã¹ããå€§å¹ ã«äœäžãããããšãã§ããã
ïŒ3ïŒæ¬åéã®å¿çååãä¿é²ããæ¹æ³ã¯ãé«ãå¿ç现èååçãæãã1åã®å¹¹çŽ°èãã24åã®å¿ç现èãçæããåæéžå¥åŸã®å¿ç现èã®ååçã86ïŒ ã«éããæé©ååŸã®å¿ç现èã®ååçã98.3ïŒ ãšé«ãïŒH7ããèæ§å¹¹çŽ°èç³»ïŒãå¿ç现èãæ¿çž®ç²Ÿè£œããŠåŸãããå¿ç现èã®çŽåºŠãããé«ãã99.9ïŒ ã«éããã
ãã®ãããæ¬çºæã¯é¢é£ãã现èæ²»çã«ããè¯ãçç¥ã®åè£ãæäŸããã
以äžãå
·äœçãªå®æœäŸã«ãã£ãŠãããã«æ¬çºæã説æããããããã®å®æœäŸã¯æ¬çºæã説æããããã«çšãããããã®ã ãã§ãæ¬çºæã®ç¯å²ã®å¶éã«ã¯ãªããªããšç解ããããã®ã§ããã以äžã®å®æœäŸã§å
·äœçãªæ¡ä»¶ã瀺ãããŠããªãå®éšæ¹æ³ã¯ãéåžžãããšãã°Sambrookãããã¢ã¬ãã¥ã©ãŒã»ã¯ããŒãã³ã°ïŒç 究宀ããã¥ã¢ã«ã(ãã¥ãŒãšãŒã¯ãã³ãŒã«ãã»ã¹ããªã³ã°ã»ããŒããŒç 究æåºç瀟ã1989) ã«èšèŒã®æ¡ä»¶ãªã©ã®éåžžã®æ¡ä»¶ã«ããããã¯ãã¡ãŒã«ãŒã®ãèŠãã®æ¡ä»¶ã«åŸããç¹ã«èª¬æããªãéããçŸåçããã³éšã¯ééçŸåçããã³éééšã§ããã
å
±éã®æ¹æ³
ããå€èœæ§çŽ°èã®å¹é€
3æ ªã®ããèæ§å¹¹çŽ°èç³»H9-cTnT-eGFPãH9ããã³H7ã¯ç±³åœWiCell幹现èãã³ã¯ããè³Œå ¥ããã(H9-hTnnTZ-pGZ-D2ãWA09åWA07)ã人工å€èœæ§å¹¹çŽ°èç³»hiPS-U-Q1ã¯æ¬å®éšå®€ã§è£Žç«¯å¿å®éšã«ãã£ãŠå ±åãããæ¹æ³ã«åŸããDOX(Sigma-Aldrich)èªå°çºçŸOKSMåå åã¬ã³ããŠã€ã«ã¹ç³»ã§ãã尿现è(è äžç®è±èœçŽ°è)ããªããã°ã©ãã³ã°ããŠåŸããããããå€èœæ§å¹¹çŽ°èç³»ã¯ããããCF1ããŠã¹èèç¹ç¶èœçŽ°èãããªãæ é€èã§å¹é€ãããå¹å°ã¯æšæºã®ããèæ§å¹¹çŽ°èå¹å°ã§ãDMEM/F12åºç€å¹å°ã«20ïŒ ã®ããã¯ã¢ãŠãè¡æž 代æ¿ç©ã10ng/ml ããbFGFã1mM L-ã°ã«ã¿ãã³ã0.1mM NEAA(以äžããããInvitrogenãã)ããã³0.1 mM β-ã¡ã«ã«ãããšã¿ããŒã«(Sigma-Aldrich)ãæ·»å ãããã®ã§ãã£ããç¡æ é€èå¹é€ã«é¢ããmTeSR1å¹å°(STEMCELL Technologies)ã«ããqualified Matrigel(BD Biosciences)ãé åããçµã¿åããã§ããå€èœæ§å¹¹çŽ°èã¯ããŒã³ããã³åå±€ã®çé·ãç¶æããã
ããå€èœæ§çŽ°èã®å¹é€
3æ ªã®ããèæ§å¹¹çŽ°èç³»H9-cTnT-eGFPãH9ããã³H7ã¯ç±³åœWiCell幹现èãã³ã¯ããè³Œå ¥ããã(H9-hTnnTZ-pGZ-D2ãWA09åWA07)ã人工å€èœæ§å¹¹çŽ°èç³»hiPS-U-Q1ã¯æ¬å®éšå®€ã§è£Žç«¯å¿å®éšã«ãã£ãŠå ±åãããæ¹æ³ã«åŸããDOX(Sigma-Aldrich)èªå°çºçŸOKSMåå åã¬ã³ããŠã€ã«ã¹ç³»ã§ãã尿现è(è äžç®è±èœçŽ°è)ããªããã°ã©ãã³ã°ããŠåŸããããããå€èœæ§å¹¹çŽ°èç³»ã¯ããããCF1ããŠã¹èèç¹ç¶èœçŽ°èãããªãæ é€èã§å¹é€ãããå¹å°ã¯æšæºã®ããèæ§å¹¹çŽ°èå¹å°ã§ãDMEM/F12åºç€å¹å°ã«20ïŒ ã®ããã¯ã¢ãŠãè¡æž 代æ¿ç©ã10ng/ml ããbFGFã1mM L-ã°ã«ã¿ãã³ã0.1mM NEAA(以äžããããInvitrogenãã)ããã³0.1 mM β-ã¡ã«ã«ãããšã¿ããŒã«(Sigma-Aldrich)ãæ·»å ãããã®ã§ãã£ããç¡æ é€èå¹é€ã«é¢ããmTeSR1å¹å°(STEMCELL Technologies)ã«ããqualified Matrigel(BD Biosciences)ãé åããçµã¿åããã§ããå€èœæ§å¹¹çŽ°èã¯ããŒã³ããã³åå±€ã®çé·ãç¶æããã
幹现èã®å¿ç现èãžã®ååãä¿é²ããå°ååã®éžå¥
Murryå®éšå®€ã«ãã£ãŠç¢ºç«ãããåå±€ååç³»ã«åºã¥ããæ¬çºæã¯åºç€å¹é€æ¶²mTeSR1ããã³RPMI/B27ã®ãŸãŸã§ã液亀æããã³èªå°å åã®æ·»å ã®æç¹ããã®ãŸãŸã§ãããã«Wntã·ã°ãã«çµè·¯ã®å¿çååã«ãããä¿é²åŸæå¶ã®æ©èœãåãããWnt3aãã¢ã¯ããã³Aããã³BMP4ã®ä»£ããã«CHIR99021(Selleck)ã䜿çšããããã«DKK1(PeproTech)ã®ä»£ããã«XAV939 (Enzo)ããã³KY02111(TOCRIS)ã䜿çšããããã®å ã®ååæ¹æ³ã«ãã£ãŠãH9-cTnT-eGFPã«ãããŠçŽ10ïŒ ã®å¿çååå¹çãåŸãããããããåœè©²æ¹æ³ã«åºã¥ããå¿çååãä¿é²ããå°ååååç©ãéžå¥ãããH9-cTnT-eGFPã48ãŠã§ã«ãã¬ãŒãã«æ¥çš®ããå°ååã®åè£ãé©åãªæ¿åºŠåŸé ã§3æ¥ç®ããå ¥ãã12æ¥ç®ã«é€å»ããã15æ¥ç®ã«ãåãŠã§ã«ã«ãããç·è²èå ã®åŒ·åºŠã芳å¯ããããšã«ãã£ãŠååå¹çãæ¯èŒããã
æ¬å®éšã§éžå¥ãããå°ååååç©ã¯ãããã幹现èã®åºæ¬ã®ã·ã°ãã«çµè·¯ã®æå¶å€ãŸãã¯ä¿é²å€ãªãã³ã«å ±åãããå°ååãšå¹¹çŽ°èååã«é¢é£ããå°ååã§ãLiClãHN4Clãã©ããã€ã·ã³ãLY294002ããŠã©ã«ããã³ãã³ãPD98059ãPD0325901ãSB431542ãSB203580ãSP600125ãã¬ããã€ã³é žãã¢ã·ã¢ãé ž.ãY27632ããã¢ãŸããã³ãz-VAD-FMKãVPAãTSAãVO-OHpicãSF1670ãKU-55933ãã¬ã¹ãã©ãããŒã«ãSTR1720ãCX-4945ãABT-737ããã¥ãŒããªã³-3ãããã£ã¹ãªã³-αãããã£ã¹ãªã³-ÎŒãGSK1904529AãFG-4592ãå«ãã
Murryå®éšå®€ã«ãã£ãŠç¢ºç«ãããåå±€ååç³»ã«åºã¥ããæ¬çºæã¯åºç€å¹é€æ¶²mTeSR1ããã³RPMI/B27ã®ãŸãŸã§ã液亀æããã³èªå°å åã®æ·»å ã®æç¹ããã®ãŸãŸã§ãããã«Wntã·ã°ãã«çµè·¯ã®å¿çååã«ãããä¿é²åŸæå¶ã®æ©èœãåãããWnt3aãã¢ã¯ããã³Aããã³BMP4ã®ä»£ããã«CHIR99021(Selleck)ã䜿çšããããã«DKK1(PeproTech)ã®ä»£ããã«XAV939 (Enzo)ããã³KY02111(TOCRIS)ã䜿çšããããã®å ã®ååæ¹æ³ã«ãã£ãŠãH9-cTnT-eGFPã«ãããŠçŽ10ïŒ ã®å¿çååå¹çãåŸãããããããåœè©²æ¹æ³ã«åºã¥ããå¿çååãä¿é²ããå°ååååç©ãéžå¥ãããH9-cTnT-eGFPã48ãŠã§ã«ãã¬ãŒãã«æ¥çš®ããå°ååã®åè£ãé©åãªæ¿åºŠåŸé ã§3æ¥ç®ããå ¥ãã12æ¥ç®ã«é€å»ããã15æ¥ç®ã«ãåãŠã§ã«ã«ãããç·è²èå ã®åŒ·åºŠã芳å¯ããããšã«ãã£ãŠååå¹çãæ¯èŒããã
æ¬å®éšã§éžå¥ãããå°ååååç©ã¯ãããã幹现èã®åºæ¬ã®ã·ã°ãã«çµè·¯ã®æå¶å€ãŸãã¯ä¿é²å€ãªãã³ã«å ±åãããå°ååãšå¹¹çŽ°èååã«é¢é£ããå°ååã§ãLiClãHN4Clãã©ããã€ã·ã³ãLY294002ããŠã©ã«ããã³ãã³ãPD98059ãPD0325901ãSB431542ãSB203580ãSP600125ãã¬ããã€ã³é žãã¢ã·ã¢ãé ž.ãY27632ããã¢ãŸããã³ãz-VAD-FMKãVPAãTSAãVO-OHpicãSF1670ãKU-55933ãã¬ã¹ãã©ãããŒã«ãSTR1720ãCX-4945ãABT-737ããã¥ãŒããªã³-3ãããã£ã¹ãªã³-αãããã£ã¹ãªã³-ÎŒãGSK1904529AãFG-4592ãå«ãã
ããå€èœæ§å¹¹çŽ°èåå±€ã«ãã£ãŠå¿ç现èãžã®ååãèªå°ããæ¹æ³
ååã®åã«ã幹现èã¯ããŒã³ã¯ç¡æ é€èã®æ¡ä»¶ã§1åç¶ä»£å¹é€ããåŸãé µçŽ (Accutase)(Invitrogen)ãåæ£ãããŠå现èã«æ¶åããå°ãªããšã1代åå±€å¹é€ãããååãæºåããæãå现èã«æ¶åã»åæ£ããããå€èœæ§å¹¹çŽ°èã5x104/cm2ã®å¯åºŠã§äºåã«åºåºèãããªãã¯ã¹(Matrigel)ã被èŠããŠãããå¹é€ãã¬ãŒãã«æ¥çš®ããããå€èœæ§å¹¹çŽ°èå¹å°(mTeSR1)ã§2æ¥å¹é€ããããããã®3æ¥ã¯ããå€èœæ§å¹¹çŽ°èå¹å°(mTeSR1)ã«10 nM ã©ããã€ã·ã³(Gene Operation)ããã³12 ÎŒM CHIRãæ·»å ããå¹é€æ¶²ã®äœ¿çšäœç©ã¯24ãŠã§ã«ãã¬ãŒãã«0.5mlã§ã12ãŠã§ã«ãã¬ãŒãã«1mlã§ã®ããã«ããæ¯æ¥æ¶²äº€æãè¡ã£ããããããã10 nM ã©ããã€ã·ã³ããã³12 ÎŒM CHIRãæ·»å ããã€ã³ã¹ãªã³ãå«ãŸãªãRPMI/B27å¹å°(RPMI/B27 minus insulin)å¹é€æ¶²ã«äº€æãã1æ¥å¹é€ããåŸã10 ÎŒM XAV939ããã³10 ÎŒM KY02111ãæ·»å ããã€ã³ã¹ãªã³ãå«ãŸãªãRPMI/B27å¹é€æ¶²ã«äº€æããé£ç¶4æ¥å¹é€ããŠãã®4æ¥å ã§å¹é€æ¶²ã亀æããªãã£ããäœãã®å°ååãæ·»å ããŠããªãã€ã³ã¹ãªã³ãå«ãŸãªãRPMI/å¹å°(Invitrogen)åºç€å¹é€æ¶²ãç¶ããŠ2æ¥å¹é€ããåŸãã€ã³ã¹ãªã³ãå«ãRPMI/B27å¹å°(Invitrogen)åºç€å¹é€æ¶²ã§ç¶æå¹é€ãè¡ãã3æ¥ã«1å液亀æãè¡ã£ããæš¡åŒå³ã¯å³1Eã«ç€ºãã
ååã®åã«ã幹现èã¯ããŒã³ã¯ç¡æ é€èã®æ¡ä»¶ã§1åç¶ä»£å¹é€ããåŸãé µçŽ (Accutase)(Invitrogen)ãåæ£ãããŠå现èã«æ¶åããå°ãªããšã1代åå±€å¹é€ãããååãæºåããæãå现èã«æ¶åã»åæ£ããããå€èœæ§å¹¹çŽ°èã5x104/cm2ã®å¯åºŠã§äºåã«åºåºèãããªãã¯ã¹(Matrigel)ã被èŠããŠãããå¹é€ãã¬ãŒãã«æ¥çš®ããããå€èœæ§å¹¹çŽ°èå¹å°(mTeSR1)ã§2æ¥å¹é€ããããããã®3æ¥ã¯ããå€èœæ§å¹¹çŽ°èå¹å°(mTeSR1)ã«10 nM ã©ããã€ã·ã³(Gene Operation)ããã³12 ÎŒM CHIRãæ·»å ããå¹é€æ¶²ã®äœ¿çšäœç©ã¯24ãŠã§ã«ãã¬ãŒãã«0.5mlã§ã12ãŠã§ã«ãã¬ãŒãã«1mlã§ã®ããã«ããæ¯æ¥æ¶²äº€æãè¡ã£ããããããã10 nM ã©ããã€ã·ã³ããã³12 ÎŒM CHIRãæ·»å ããã€ã³ã¹ãªã³ãå«ãŸãªãRPMI/B27å¹å°(RPMI/B27 minus insulin)å¹é€æ¶²ã«äº€æãã1æ¥å¹é€ããåŸã10 ÎŒM XAV939ããã³10 ÎŒM KY02111ãæ·»å ããã€ã³ã¹ãªã³ãå«ãŸãªãRPMI/B27å¹é€æ¶²ã«äº€æããé£ç¶4æ¥å¹é€ããŠãã®4æ¥å ã§å¹é€æ¶²ã亀æããªãã£ããäœãã®å°ååãæ·»å ããŠããªãã€ã³ã¹ãªã³ãå«ãŸãªãRPMI/å¹å°(Invitrogen)åºç€å¹é€æ¶²ãç¶ããŠ2æ¥å¹é€ããåŸãã€ã³ã¹ãªã³ãå«ãRPMI/B27å¹å°(Invitrogen)åºç€å¹é€æ¶²ã§ç¶æå¹é€ãè¡ãã3æ¥ã«1å液亀æãè¡ã£ããæš¡åŒå³ã¯å³1Eã«ç€ºãã
å¿ç现èå
ç«èå
1ïŒæäœ
æcTnTãæαã¢ã¯ããã³(CST)æäœ
Alexa-488-æããŠã¹ãAlexa-555-æããŠã¹(Invitrogen)äºæ¬¡æäœ
2ïŒå®éšæé
ïŒ1ïŒå®å šå¹å°ãé€å»ããPBSã§çŽ°èã1åæŽæµããã
ïŒ2ïŒ4ïŒ ã®ãã©ãã«ã ã¢ã«ããã(Sigma-Aldrich)ã§å®€æž©ã§15åéåºå®åããã
ïŒ3ïŒPBSã§å®€æž©ã§æ¯å5åéã§3åæŽæµããã
ïŒ4ïŒ0.1ïŒ Triton-X-100(Sigma-Aldrich)ãå«ãPBSã§å®€æž©ã§15åéééååŠçããã
ïŒ5ïŒPBSã§å®€æž©ã§æ¯å10åéã§3åæŽæµããã
ïŒ6ïŒ5ïŒ ã€ã®è¡æž (Invitrogen)ãå«ãPBSã§å®€æž©ã§1æéããããã³ã°ããã
ïŒ7ïŒ1ïŒ250ã§æcTnTãæαã¢ã¯ããã³æäœãå ¥ãã4âã§äžæ©ã€ã³ãã¥ããŒãããã
ïŒ8ïŒPBSã§å®€æž©ã§æ¯å10åéã§3åæŽæµããã
ïŒ9ïŒ1ïŒ1000ã§çžå¿ããèå äºæ¬¡æäœãå ¥ãã宀枩ã§å ãé¿ããŠ1æéã€ã³ãã¥ããŒãããã
ïŒ10ïŒäºæ¬¡æäœãåžãåããPBSã§å®€æž©ã§æ¯å10åéã§3åæŽæµããã
ïŒ11ïŒ1ïŒ2000ã§DAPIæè²æ¶²ãå ¥ããŠå®€æž©ã§5åéã€ã³ãã¥ããŒãããPBSã§å®€æž©ã§æ¯å10åéã§1åæŽæµããã
ïŒ12ïŒå°æ¢å€ã§å°ããèå é¡åŸ®é¡ã§çµæã芳å¯ãããªãªã³ãã¹èå é¡åŸ®é¡ã§å ç«èå åçãæ®åœ±ããã
1ïŒæäœ
æcTnTãæαã¢ã¯ããã³(CST)æäœ
Alexa-488-æããŠã¹ãAlexa-555-æããŠã¹(Invitrogen)äºæ¬¡æäœ
2ïŒå®éšæé
ïŒ1ïŒå®å šå¹å°ãé€å»ããPBSã§çŽ°èã1åæŽæµããã
ïŒ2ïŒ4ïŒ ã®ãã©ãã«ã ã¢ã«ããã(Sigma-Aldrich)ã§å®€æž©ã§15åéåºå®åããã
ïŒ3ïŒPBSã§å®€æž©ã§æ¯å5åéã§3åæŽæµããã
ïŒ4ïŒ0.1ïŒ Triton-X-100(Sigma-Aldrich)ãå«ãPBSã§å®€æž©ã§15åéééååŠçããã
ïŒ5ïŒPBSã§å®€æž©ã§æ¯å10åéã§3åæŽæµããã
ïŒ6ïŒ5ïŒ ã€ã®è¡æž (Invitrogen)ãå«ãPBSã§å®€æž©ã§1æéããããã³ã°ããã
ïŒ7ïŒ1ïŒ250ã§æcTnTãæαã¢ã¯ããã³æäœãå ¥ãã4âã§äžæ©ã€ã³ãã¥ããŒãããã
ïŒ8ïŒPBSã§å®€æž©ã§æ¯å10åéã§3åæŽæµããã
ïŒ9ïŒ1ïŒ1000ã§çžå¿ããèå äºæ¬¡æäœãå ¥ãã宀枩ã§å ãé¿ããŠ1æéã€ã³ãã¥ããŒãããã
ïŒ10ïŒäºæ¬¡æäœãåžãåããPBSã§å®€æž©ã§æ¯å10åéã§3åæŽæµããã
ïŒ11ïŒ1ïŒ2000ã§DAPIæè²æ¶²ãå ¥ããŠå®€æž©ã§5åéã€ã³ãã¥ããŒãããPBSã§å®€æž©ã§æ¯å10åéã§1åæŽæµããã
ïŒ12ïŒå°æ¢å€ã§å°ããèå é¡åŸ®é¡ã§çµæã芳å¯ãããªãªã³ãã¹èå é¡åŸ®é¡ã§å ç«èå åçãæ®åœ±ããã
å¿ç现èé»åé¡åŸ®é¡å®éš
ïŒ1ïŒå¹é€æ¶²ãé€å»ãã1mlã®2ïŒ ã°ã«ã¿ã«ã¢ã«ããããå ¥ãã现èãå¥ããã4âã§äžæ©åºå®åããã
ïŒ2ïŒ0.25ïŒ ãªã¹ããŠã /0.25ïŒ K4Fe(CN)6ã§4âã§15ã30åéåºå®åããã
ïŒ3ïŒPBSã§4âã§æ¯å10åéã§3åæŽæµããã
ïŒ4ïŒäžé£ã®ã¢ã»ãã³ã§å®€æž©ã§è±æ°Žãããã
50ïŒ ã¢ã»ãã³æº¶æ¶²ã§1å10åéè±æ°Žãããã
70ïŒ ã¢ã»ãã³æº¶æ¶²ã§1å10åéè±æ°Žãããã
90ïŒ ã¢ã»ãã³æº¶æ¶²ã§æ¯å10åéã§2åè±æ°Žãããã
100ïŒ ã¢ã»ãã³æº¶æ¶²ã§æ¯å10åéã§3åè±æ°Žãããã
ïŒ5ïŒæµžéïŒç¶ã«ãããè±æ°Žå€ãåžãåãã3mLã®ã¢ã»ãã³-EPON812å åå€(äœç©æ¯1:1)ãå ¥ãã宀枩ã§30åé眮ããåŸãåžéããå åå€ãæšãŠãå åå€ã ãã1mLå ¥ãã宀枩ã§2æéãŸãã¯äžæ©çœ®ããã
ïŒ6ïŒå åïŒæ··åå åå€ãåžãåã£ãŠã«ãã»ã«ã¢ãžã¥ãŒã«ãŠã§ã«ã®åºéšã«ãã£ã±ããŸã§æ»Žäžãã现èå£å¡ãã«ãã»ã«ã®åºéšã«äž¡æ«ç«¯ã«è¿ã¥ãããã«ç§»ãã60âã®ãªãŒãã³ã§2æéå ç±ãã硬ããããã¯ã«ä¹Ÿç¥ãããã
ïŒ7ïŒãããã¯ã®èª¿æŽïŒå åãããã¯ãç¹è£œã®æ²»å ·ã«åãä»ããé¡åŸ®é¡ã§çåãã€ãã§è¡šé¢ã®å åå€ãé€å»ããã
ïŒ8ïŒåçïŒãŸãå åãããã¯ãè¶ èåçæ©ã«åºå®ããåãçŽ1ÎŒmã®æºè¶ èåçãåãåºããããããã·ãªã³-ãšãªãžã³æè²æ³ã«ãã£ãŠæè²ãããé¡åŸ®é¡ã§çŽ°èã®ç»åã芳å¯ããè¶ èåçãè¡ãéšäœã確èªããæšèãã€ãããÏ3mmã150ã200ã¡ãã·ã¥ã®é 網ãçšæããæŽæµæ¶²ãæŽæµãããã€ç¡æ°Žãšã¿ããŒã«ã§è±æ°ŽããŠä¹Ÿç¥ãããæ¯æèã調補ããæ éã«é 網ã«çœ®ãããè¶ èåçæ©ã«äžè§åœ¢ã®ã¬ã©ã¹ãã¬ãŒããåãä»ããå åãããã¯ãåºå®ããåã50ã70nmã®è¶ èåçãåãåºãããŸã€ããã©ã·ã§åçãåã£ãŠéŒç·ãªã³ã°ã§åãåããé 網ã®æ¯æèåŽã«è²Œãä»ãã也ç¥å®¹åšã§æè²ãŸã§ä¿åããã
ïŒ9ïŒé»åæè²ïŒããããªæ¯ç§ãã©ãã£ã³ãã¬ãŒãã眮ããããããªå¹é€ã·ã£ãŒã¬ãçšæããããã©ãã£ã³ãã¬ãŒãã«é ¢é žãããªãŠã æè²æ¶²ã1ãæ°æ»Žæ»Žäžãããã³ã»ããã§ç¶²ã®çžãåããåçã貌ãä»ããé¢ãäžã«åãããã«ã網ã液滎ã«æµ®ãã°ããå¹é€ã·ã£ãŒã¬ã«èãããŠ5ã30åéæè²ããæè²åŸããåèžçæ°Žã§3åæŽæµããããçŽã§ç¶²ã«ã€ããäœåã®æ°Žåãåžãåããå¹é€ã·ã£ãŒã¬ã«çœ®ããŠèªç¶ä¹Ÿç¥ãããããã«ã網ãããäžã€ã®ãã©ãã£ã³ãã¬ãŒããå ¥ããå¹é€ã·ã£ãŒã¬ã«çœ®ããŠåæ§ã®æ¹æ³ã«ãã£ãŠã¯ãšã³é žéã®æè²ããã³æŽæµãè¡ã£ããåçã¯æè²åŸä¹Ÿç¥ããŠãã芳å¯ããã
ïŒ10ïŒæåŸã«ã©ã€ã«FEI Tecnai G2 Spirit TEMééåé»åé¡åŸ®é¡ã§èŠ³å¯ããŠæ®åœ±ããã
ïŒ1ïŒå¹é€æ¶²ãé€å»ãã1mlã®2ïŒ ã°ã«ã¿ã«ã¢ã«ããããå ¥ãã现èãå¥ããã4âã§äžæ©åºå®åããã
ïŒ2ïŒ0.25ïŒ ãªã¹ããŠã /0.25ïŒ K4Fe(CN)6ã§4âã§15ã30åéåºå®åããã
ïŒ3ïŒPBSã§4âã§æ¯å10åéã§3åæŽæµããã
ïŒ4ïŒäžé£ã®ã¢ã»ãã³ã§å®€æž©ã§è±æ°Žãããã
50ïŒ ã¢ã»ãã³æº¶æ¶²ã§1å10åéè±æ°Žãããã
70ïŒ ã¢ã»ãã³æº¶æ¶²ã§1å10åéè±æ°Žãããã
90ïŒ ã¢ã»ãã³æº¶æ¶²ã§æ¯å10åéã§2åè±æ°Žãããã
100ïŒ ã¢ã»ãã³æº¶æ¶²ã§æ¯å10åéã§3åè±æ°Žãããã
ïŒ5ïŒæµžéïŒç¶ã«ãããè±æ°Žå€ãåžãåãã3mLã®ã¢ã»ãã³-EPON812å åå€(äœç©æ¯1:1)ãå ¥ãã宀枩ã§30åé眮ããåŸãåžéããå åå€ãæšãŠãå åå€ã ãã1mLå ¥ãã宀枩ã§2æéãŸãã¯äžæ©çœ®ããã
ïŒ6ïŒå åïŒæ··åå åå€ãåžãåã£ãŠã«ãã»ã«ã¢ãžã¥ãŒã«ãŠã§ã«ã®åºéšã«ãã£ã±ããŸã§æ»Žäžãã现èå£å¡ãã«ãã»ã«ã®åºéšã«äž¡æ«ç«¯ã«è¿ã¥ãããã«ç§»ãã60âã®ãªãŒãã³ã§2æéå ç±ãã硬ããããã¯ã«ä¹Ÿç¥ãããã
ïŒ7ïŒãããã¯ã®èª¿æŽïŒå åãããã¯ãç¹è£œã®æ²»å ·ã«åãä»ããé¡åŸ®é¡ã§çåãã€ãã§è¡šé¢ã®å åå€ãé€å»ããã
ïŒ8ïŒåçïŒãŸãå åãããã¯ãè¶ èåçæ©ã«åºå®ããåãçŽ1ÎŒmã®æºè¶ èåçãåãåºããããããã·ãªã³-ãšãªãžã³æè²æ³ã«ãã£ãŠæè²ãããé¡åŸ®é¡ã§çŽ°èã®ç»åã芳å¯ããè¶ èåçãè¡ãéšäœã確èªããæšèãã€ãããÏ3mmã150ã200ã¡ãã·ã¥ã®é 網ãçšæããæŽæµæ¶²ãæŽæµãããã€ç¡æ°Žãšã¿ããŒã«ã§è±æ°ŽããŠä¹Ÿç¥ãããæ¯æèã調補ããæ éã«é 網ã«çœ®ãããè¶ èåçæ©ã«äžè§åœ¢ã®ã¬ã©ã¹ãã¬ãŒããåãä»ããå åãããã¯ãåºå®ããåã50ã70nmã®è¶ èåçãåãåºãããŸã€ããã©ã·ã§åçãåã£ãŠéŒç·ãªã³ã°ã§åãåããé 網ã®æ¯æèåŽã«è²Œãä»ãã也ç¥å®¹åšã§æè²ãŸã§ä¿åããã
ïŒ9ïŒé»åæè²ïŒããããªæ¯ç§ãã©ãã£ã³ãã¬ãŒãã眮ããããããªå¹é€ã·ã£ãŒã¬ãçšæããããã©ãã£ã³ãã¬ãŒãã«é ¢é žãããªãŠã æè²æ¶²ã1ãæ°æ»Žæ»Žäžãããã³ã»ããã§ç¶²ã®çžãåããåçã貌ãä»ããé¢ãäžã«åãããã«ã網ã液滎ã«æµ®ãã°ããå¹é€ã·ã£ãŒã¬ã«èãããŠ5ã30åéæè²ããæè²åŸããåèžçæ°Žã§3åæŽæµããããçŽã§ç¶²ã«ã€ããäœåã®æ°Žåãåžãåããå¹é€ã·ã£ãŒã¬ã«çœ®ããŠèªç¶ä¹Ÿç¥ãããããã«ã網ãããäžã€ã®ãã©ãã£ã³ãã¬ãŒããå ¥ããå¹é€ã·ã£ãŒã¬ã«çœ®ããŠåæ§ã®æ¹æ³ã«ãã£ãŠã¯ãšã³é žéã®æè²ããã³æŽæµãè¡ã£ããåçã¯æè²åŸä¹Ÿç¥ããŠãã芳å¯ããã
ïŒ10ïŒæåŸã«ã©ã€ã«FEI Tecnai G2 Spirit TEMééåé»åé¡åŸ®é¡ã§èŠ³å¯ããŠæ®åœ±ããã
å®æœäŸ1 ãã幹现èã®å¿ç现èãžã®ååãä¿é²ããå°ååååç©ã®éžå¥
H9-cTnT-eGFPããèæ§å¹¹çŽ°èç³»ãã¬ããŒã¿ãŒã·ã¹ãã ãšããŠäœ¿çšããç¡ãµã€ãã«ã€ã³ããã³é«å¯åºŠåå±€å¹é€èªå°ã®æ¡ä»¶ã«ãããŠã幹现èã®å¿ç现èãžã®å¹ççãªååãä¿é²ããããšãã§ããå°ååååç©ãéžå¥ããã
倧éã®éžå¥ã«ãã£ãŠãmTORã·ã°ãã«çµè·¯æå¶å€ã§ããã©ããã€ã·ã³ïŒRapamycinïŒãšWntçµè·¯ä¿é²å€ã§ããCHIR99021ã®çµã¿åããã¯é¡èã«ãã幹现èã®å¿ç现èãžã®ååãä¿é²ããããšãã§ããããšãèŠåºãããã
H9-cTnT-eGFPããèæ§å¹¹çŽ°èç³»ãã¬ããŒã¿ãŒã·ã¹ãã ãšããŠäœ¿çšããç¡ãµã€ãã«ã€ã³ããã³é«å¯åºŠåå±€å¹é€èªå°ã®æ¡ä»¶ã«ãããŠã幹现èã®å¿ç现èãžã®å¹ççãªååãä¿é²ããããšãã§ããå°ååååç©ãéžå¥ããã
倧éã®éžå¥ã«ãã£ãŠãmTORã·ã°ãã«çµè·¯æå¶å€ã§ããã©ããã€ã·ã³ïŒRapamycinïŒãšWntçµè·¯ä¿é²å€ã§ããCHIR99021ã®çµã¿åããã¯é¡èã«ãã幹现èã®å¿ç现èãžã®ååãä¿é²ããããšãã§ããããšãèŠåºãããã
å®æœäŸ2 ã©ããã€ã·ã³ãšCHIR99021ã®äœµçšã«ãããã幹现èã®å¿ç现èãžã®ååã«å¯Ÿããä¿é²
åæéžå¥ã®çµæïŒ
çµæãå³1Aã«ç€ºããçµæãããmTORã·ã°ãã«çµè·¯æå¶å€ã§ããã©ããã€ã·ã³ïŒRapamycinïŒãšWntçµè·¯ä¿é²å€ã§ããCHIR99021ã®äœµçšã¯é¡èã«ãã幹现èïŒH9现èç³»ïŒã®å¿ç现èãžã®ååã®å¹çãåäžããã86ïŒ ã«éããããšã瀺ããããäžæ¹ãåç¬ã§CHIR99021ã䜿çšããŠåŸãããå¿ç现èã®ååçã¯çŽ15ïŒ ãšäœããåç¬ã§ã©ããã€ã·ã³ã䜿çšããŠåŸãããå¿ç现èã®ååå¹çã¯ã»ãšãã©0ã§ãã£ãã
åæéžå¥ã®çµæïŒ
çµæãå³1Aã«ç€ºããçµæãããmTORã·ã°ãã«çµè·¯æå¶å€ã§ããã©ããã€ã·ã³ïŒRapamycinïŒãšWntçµè·¯ä¿é²å€ã§ããCHIR99021ã®äœµçšã¯é¡èã«ãã幹现èïŒH9现èç³»ïŒã®å¿ç现èãžã®ååã®å¹çãåäžããã86ïŒ ã«éããããšã瀺ããããäžæ¹ãåç¬ã§CHIR99021ã䜿çšããŠåŸãããå¿ç现èã®ååçã¯çŽ15ïŒ ãšäœããåç¬ã§ã©ããã€ã·ã³ã䜿çšããŠåŸãããå¿ç现èã®ååå¹çã¯ã»ãšãã©0ã§ãã£ãã
æé©åã®çµæïŒ
CHIRïŒ10nMïŒã§ããèæ§å¹¹çŽ°èãåŠçããåŸãã©ããã€ã·ã³ïŒ10nMïŒåŠçã®æéçªã®æé©åã«ãã£ãŠãçºæè ã¯æå®ã®æç¹ã§ã©ããã€ã·ã³ãæ·»å ã»é€å»ãããåå±€ååã®ç¹åŸŽãšå¿çååã®æ®µéæ§ãããååå šäœã3ã€ã®æ®µéãããªãã¡-3ãã1æ¥ç®ã®å èè圢æ段é(0æ¥ç®ãèªå°ååã®éå§æéãããªãã¡å€èœæ§å¹¹çŽ°èå¹é€æ¶²mTeSR1ãèªå°ååå¹é€æ¶²RPMI1640-B27ã«æããæç¹ãšå®çŸ©ãã)ã1ã5æ¥ç®ã®å¿çåé§çŽ°èèªå°æ®µéã5æ¥ç®ä»¥éã®å¿ç现èåºçŸã»å¢å¹ 段éã«åããã30æ¥ç®ã«ãH9-cTnT-eGFPãååãããŠåŸãããå¿ç现èã®æ¯çãæ€åºããããšã«ãã£ãŠãçºæè ã¯å¿çååéå§æ®µéã§ã©ããã€ã·ã³ãå ¥ãããš93.5±2.1ïŒ ã®å¿ç现èãçæã(å³1B)ãåã®å šéçšã§ã©ããã€ã·ã³ãå ¥ããå Žåã®èªå°å¹çãããé«ãã£ãããšãèŠåºãããåæã«ãã©ããã€ã·ã³ã®åŠçæéã延ã°ããšæçµã®å¿ç现èã®æ¯çãæžå°ããã ãã§ã¯ãªããé¡èã«å¿ç现èã®åéãäœäžãããããšãèŠåºããïŒå³1CïŒã1ã5æ¥ç®ãŸãã¯5ã8æ¥ç®ã ãã§ã©ããã€ã·ã³ãå ¥ãããšãçæããå¿ç现èã®æ¯çãéåžžã«äœãããã€å€ãã®å Žå现èã5æ¥ç®ã«å šéšæ»äº¡ããå¿ç现èãåŸãããšãã§ããªãã£ãã
ã©ããã€ã·ã³(Rapamycin)ãšCHIRã®äœµçšã«ããå¿çååä¿é²äœçšããã³åœè©²æ¹æ³ã®ç°ãªãããå€èœæ§å¹¹çŽ°èã®éã«ãããæ®éçé©å¿æ§ãæ€åºããããã«ãçºæè ã¯äžèšæé©åã®ååæ¹æ³ãã»ãã®3æ ªã®ããå€èœæ§å¹¹çŽ°èç³»ïŒããèæ§å¹¹çŽ°èH7ãH9ããã³ããiPS幹现èç³»U-Q1ïŒã«ç§»æ€ãããã€ããããH9ãH7ãU-Q1现èç³»ã®å¿ç现èã®ååå¹çãæ€åºããã
CHIRïŒ10nMïŒã§ããèæ§å¹¹çŽ°èãåŠçããåŸãã©ããã€ã·ã³ïŒ10nMïŒåŠçã®æéçªã®æé©åã«ãã£ãŠãçºæè ã¯æå®ã®æç¹ã§ã©ããã€ã·ã³ãæ·»å ã»é€å»ãããåå±€ååã®ç¹åŸŽãšå¿çååã®æ®µéæ§ãããååå šäœã3ã€ã®æ®µéãããªãã¡-3ãã1æ¥ç®ã®å èè圢æ段é(0æ¥ç®ãèªå°ååã®éå§æéãããªãã¡å€èœæ§å¹¹çŽ°èå¹é€æ¶²mTeSR1ãèªå°ååå¹é€æ¶²RPMI1640-B27ã«æããæç¹ãšå®çŸ©ãã)ã1ã5æ¥ç®ã®å¿çåé§çŽ°èèªå°æ®µéã5æ¥ç®ä»¥éã®å¿ç现èåºçŸã»å¢å¹ 段éã«åããã30æ¥ç®ã«ãH9-cTnT-eGFPãååãããŠåŸãããå¿ç现èã®æ¯çãæ€åºããããšã«ãã£ãŠãçºæè ã¯å¿çååéå§æ®µéã§ã©ããã€ã·ã³ãå ¥ãããš93.5±2.1ïŒ ã®å¿ç现èãçæã(å³1B)ãåã®å šéçšã§ã©ããã€ã·ã³ãå ¥ããå Žåã®èªå°å¹çãããé«ãã£ãããšãèŠåºãããåæã«ãã©ããã€ã·ã³ã®åŠçæéã延ã°ããšæçµã®å¿ç现èã®æ¯çãæžå°ããã ãã§ã¯ãªããé¡èã«å¿ç现èã®åéãäœäžãããããšãèŠåºããïŒå³1CïŒã1ã5æ¥ç®ãŸãã¯5ã8æ¥ç®ã ãã§ã©ããã€ã·ã³ãå ¥ãããšãçæããå¿ç现èã®æ¯çãéåžžã«äœãããã€å€ãã®å Žå现èã5æ¥ç®ã«å šéšæ»äº¡ããå¿ç现èãåŸãããšãã§ããªãã£ãã
ã©ããã€ã·ã³(Rapamycin)ãšCHIRã®äœµçšã«ããå¿çååä¿é²äœçšããã³åœè©²æ¹æ³ã®ç°ãªãããå€èœæ§å¹¹çŽ°èã®éã«ãããæ®éçé©å¿æ§ãæ€åºããããã«ãçºæè ã¯äžèšæé©åã®ååæ¹æ³ãã»ãã®3æ ªã®ããå€èœæ§å¹¹çŽ°èç³»ïŒããèæ§å¹¹çŽ°èH7ãH9ããã³ããiPS幹现èç³»U-Q1ïŒã«ç§»æ€ãããã€ããããH9ãH7ãU-Q1现èç³»ã®å¿ç现èã®ååå¹çãæ€åºããã
çµæããã®3æ ªã®å¹¹çŽ°èç³»ã®ååå¹çã¯éåžžã«é«ãã¬ãã«ã«å®å®ããããšãèŠåºããããããã§ãH7现èç³»ã¯äžèšæé©åãããååç³»ã§98.3 ± 0.76ïŒ
ã®ååå¹çã«éããããèæ§å¹¹çŽ°èç³»H9ã¯äžèšæé©åãããååç³»ã«ãããååå¹çã93.3 ± 2.1ïŒ
ã§ãããiPS现èãäžèšæé©åãããååç³»ã§90.6 ± 3.6ïŒ
ã®é«ãååå¹çã«éãã(å³1D)ã
ãã®ã»ããæ¬çºæã®ååæ¹æ³ã¯æå¹ã«ååã®å¹é€æ¶²ããã³æ·»å å€ã®æ¶èãç¯çŽããããªãã¡ã24ãŠã§ã«ãã¬ãŒãã®åãŠã§ã«ã«æ¯æ¥å¿ èŠãªå¹é€æ¶²ã1mlãã0.5mlã«äœäžãããïŒ0.5mlãããã®å¹é€æ¶²ã«10äžåã®å¹¹çŽ°èãæ¥çš®ããïŒããšãã§ããåæã«éåžžã«é«ãå¿ç现èã®çæå¹çãç¶æãã1åã®å¹¹çŽ°èãã24åã®å¿ç现èãçæãã(ååã®15æ¥ç®ã«ã«ãŠã³ããã)ã0.5mLãããã®å¹é€æ¶²ã«24Ã105åã®å¿ç现èãçæãããæçµã®æé©åãããååæ¹æ³ã¯å³1Eã«ç€ºãã
ãã®ã»ããæ¬çºæã®ååæ¹æ³ã¯æå¹ã«ååã®å¹é€æ¶²ããã³æ·»å å€ã®æ¶èãç¯çŽããããªãã¡ã24ãŠã§ã«ãã¬ãŒãã®åãŠã§ã«ã«æ¯æ¥å¿ èŠãªå¹é€æ¶²ã1mlãã0.5mlã«äœäžãããïŒ0.5mlãããã®å¹é€æ¶²ã«10äžåã®å¹¹çŽ°èãæ¥çš®ããïŒããšãã§ããåæã«éåžžã«é«ãå¿ç现èã®çæå¹çãç¶æãã1åã®å¹¹çŽ°èãã24åã®å¿ç现èãçæãã(ååã®15æ¥ç®ã«ã«ãŠã³ããã)ã0.5mLãããã®å¹é€æ¶²ã«24Ã105åã®å¿ç现èãçæãããæçµã®æé©åãããååæ¹æ³ã¯å³1Eã«ç€ºãã
å®æœäŸ3 ååç©ã«ãã£ãŠèªå°ãããå¿ç现èã®æ¿çž®ç²Ÿè£œ
åå15æ¥ã®æãå¿ç现èå¹é€æ¶²ããããŠç³ãå«ãŸãªãDMEM/F12å¹é€æ¶²ã«æããŠ10ïŒ ïŒv/vïŒã®çèå è¡æž (FBS)ãå ¥ããå¹é€éäžã§1mMã®ä¹³ç³ãå¯äžã®ççŽ æºãšããŠæ·»å ãã2æ¥ããã«æ¶²ã亀æããé£ç¶7æ¥å¹é€ãããããŒãµã€ãã¡ããªãŒã«ãã£ãŠcTnTéœæ§çŽ°èã®æ¯çãæ€åºããã
çµæããã幹现èç±æ¥ã®å¿ç现èã1mMä¹³ç³ïŒå¯äžã®ççŽ æºïŒå¹é€æ¶²ã§7æ¥å¹é€ããå¿ç现èã®çŽåºŠã99.9ïŒ ã«ããããšãã§ãïŒå³2AïŒãçµ±èšã§1åã®å¹¹çŽ°èã®æå ¥ã§24åã®å¿ç现èãçæãããã€ååãããªãå¹é€æ¶²ãšæ·»å å åãæ¶èãããããšã瀺ãããã
åå15æ¥ã®æãå¿ç现èå¹é€æ¶²ããããŠç³ãå«ãŸãªãDMEM/F12å¹é€æ¶²ã«æããŠ10ïŒ ïŒv/vïŒã®çèå è¡æž (FBS)ãå ¥ããå¹é€éäžã§1mMã®ä¹³ç³ãå¯äžã®ççŽ æºãšããŠæ·»å ãã2æ¥ããã«æ¶²ã亀æããé£ç¶7æ¥å¹é€ãããããŒãµã€ãã¡ããªãŒã«ãã£ãŠcTnTéœæ§çŽ°èã®æ¯çãæ€åºããã
çµæããã幹现èç±æ¥ã®å¿ç现èã1mMä¹³ç³ïŒå¯äžã®ççŽ æºïŒå¹é€æ¶²ã§7æ¥å¹é€ããå¿ç现èã®çŽåºŠã99.9ïŒ ã«ããããšãã§ãïŒå³2AïŒãçµ±èšã§1åã®å¹¹çŽ°èã®æå ¥ã§24åã®å¿ç现èãçæãããã€ååãããªãå¹é€æ¶²ãšæ·»å å åãæ¶èãããããšã瀺ãããã
å®æœäŸ4 ååç©ã«ãã£ãŠèªå°ãããå¿ç现èã®ç¹ç°æ§ææšã®åå®
å ç«èå æè²æè¡ã«ãã£ãŠãæ¬çºæã§ååããŠåŸãããå¿ç现èã®ãããããã®2çš®é¡ã®ã¿ã³ãã¯è³ªãçºçŸãããäžéšã®çŽ°èã§ã¯é¡èãªãµã«ã³ã¡ã¢æ§é ããã£ãããšãèŠåºãããïŒå³2BïŒãåŸãããå¿ç现èã¯å¿ç现èã®ãããªæçã®ããã³ã³ããªã¢ãæãïŒå¹¹çŽ°èã®ããã³ã³ããªã¢ã¯å°ãªããŠç圢ãå€ããããã³ã³ããªã¢å èã®ã¯ãªã¹ãæ§é ãé¡èã§ã¯ãªãïŒãè±å¯ãªçãã£ã©ã¡ã³ãæ§é ããããé¡èãªZç·ãèŠãããå¿ç现èã®éã«é¡èãªä»åšæ¿ã®ãããªçŽ°èé£çµ¡ããã£ãïŒå³2CïŒã
çµæãããæ¬çºæã®èªå°æ¹æ³ã«ããå¿ç现èã¯ãæç床ãé«ããæ£åžžã®å¿çæ©èœãçºæ®ããæ§é åºç€ãæããããšã瀺ãããã
ãã®ã»ããå¿ç现èã®ç¹ç°çéºäŒåã®çºçŸãããã¡ã€ã«ã®æ€åºã§ãæ¬çºæã®æ¹æ³ã«ãã£ãŠååããå¿ç现èã®cTnTãαMHCã Nkx2.5ãHCN4ãNav1.5ãCav3.2ãKCNQ1ãªã©ã®å¿ç现èã®ç¹ç°çæ§é éºäŒåããã³ã€ãªã³ãã£ãã«éºäŒåã®çºçŸã¬ãã«ãåŸæ¥ã®EBååæ¹æ³ã«ããå¿ç现èããã³æ人å¿ççµç¹ãšéåžžã«é¡äŒŒããããšãèŠåºãããïŒå³2DïŒã
å ç«èå æè²æè¡ã«ãã£ãŠãæ¬çºæã§ååããŠåŸãããå¿ç现èã®ãããããã®2çš®é¡ã®ã¿ã³ãã¯è³ªãçºçŸãããäžéšã®çŽ°èã§ã¯é¡èãªãµã«ã³ã¡ã¢æ§é ããã£ãããšãèŠåºãããïŒå³2BïŒãåŸãããå¿ç现èã¯å¿ç现èã®ãããªæçã®ããã³ã³ããªã¢ãæãïŒå¹¹çŽ°èã®ããã³ã³ããªã¢ã¯å°ãªããŠç圢ãå€ããããã³ã³ããªã¢å èã®ã¯ãªã¹ãæ§é ãé¡èã§ã¯ãªãïŒãè±å¯ãªçãã£ã©ã¡ã³ãæ§é ããããé¡èãªZç·ãèŠãããå¿ç现èã®éã«é¡èãªä»åšæ¿ã®ãããªçŽ°èé£çµ¡ããã£ãïŒå³2CïŒã
çµæãããæ¬çºæã®èªå°æ¹æ³ã«ããå¿ç现èã¯ãæç床ãé«ããæ£åžžã®å¿çæ©èœãçºæ®ããæ§é åºç€ãæããããšã瀺ãããã
ãã®ã»ããå¿ç现èã®ç¹ç°çéºäŒåã®çºçŸãããã¡ã€ã«ã®æ€åºã§ãæ¬çºæã®æ¹æ³ã«ãã£ãŠååããå¿ç现èã®cTnTãαMHCã Nkx2.5ãHCN4ãNav1.5ãCav3.2ãKCNQ1ãªã©ã®å¿ç现èã®ç¹ç°çæ§é éºäŒåããã³ã€ãªã³ãã£ãã«éºäŒåã®çºçŸã¬ãã«ãåŸæ¥ã®EBååæ¹æ³ã«ããå¿ç现èããã³æ人å¿ççµç¹ãšéåžžã«é¡äŒŒããããšãèŠåºãããïŒå³2DïŒã
å®æœäŸ5 ã©ããã€ã·ã³ã®ã¢ãããŒã·ã¹ãžã®æå¶ã«ããããèæ§å¹¹çŽ°èã®é«å¯åºŠåå±€å¹é€æ¡ä»¶ã«ãããçé·ã«å¯Ÿããä¿é²
ããèæ§å¹¹çŽ°èã®å¿ç现èãžã®ååã¯éåžžã«è€éã§è匱ãªéçšã§ãæ§ã ãªç°å¢èŠçŽ ã®å€åããã³çŽ°èç¶æ ã®å€åã«éåžžã«ææã§ãããç¹ã«åå±€é«å¯åºŠååæ¹æ³ã¯ãEBååæ³ãšæ¯ã¹ããã粟確ãªèª¿ç¯ã«äŸåããèªå·±åæ³ãµã€ãã«ã€ã³ã®æ¿åºŠã¬ãã«ã«ãäŸåããã©ããªå¹²æžãååå¹çã®äœäžãã²ããŠã¯å®å šãªå€±æã«ã€ãªããå¯èœæ§ãããã
ååã®éçšã«ãããŠãã©ããã€ã·ã³ã§åŠçããã现èã¯CHIRåŠç矀ã«å¯ŸããŠåœ¢æ äžã¯ããç·»å¯ã§é µçŽ æ¶åã®æããé·ãæéãå¿ èŠã§ããã€é·æéã®å¹é€éçšã§æµ®ãæ»äº¡çŽ°èãããå°ãªãããã®çŸè±¡ã確èªããããã«ãçºæè ã¯å¹é€éçšã§çŽ°èæ°ããã³çŽ°è掻æ§ã®å€åãæ€åºããã
ããããDMSOãCHIRããã³CHIR+ã©ããã€ã·ã³ãšãã3çš®é¡ã®åŠçæ¡ä»¶ã§é¢é£æ€åºãè¡ã£ãã现èèšæ°ãããDMSO溶åªã§åŠçãããå¯Ÿç §çŽ°èã«å¯ŸããCHIRã¯æåã®3æ¥ã§å¹¹çŽ°èæ°ã®å¢å ãæ©ãããããšãã§ãããã4æ¥ç®ã«çŽ°èæ°ã®æ¥æ¿ãªäœäžãæžå°ããããšãã§ããïŒ4æ¥ç®ã«å¹é€æ¶²ã亀æããããã幹现èã¯å¹é€ç°å¢ã®æ¥æ¿ãªå€åã«ãã£ãŠå€§éã«æ»äº¡ããïŒãçµæãããã©ããã€ã·ã³ã¯ããã«çŽ°èæ°ãå¢å ããããã€çŽ°èæ°ã®äœäžãæžå°ããããšãã§ããããšãèŠåºãããïŒå³3AïŒã
CCK-8ãããã§çŽ°èã«ãããè±æ°ŽçŽ é µçŽ ã®æŽ»æ§ãæ€åºããããšã«ãã£ãŠçŽ°èã®å¢æ®ã¬ãã«ãšçŽ°è掻æ§ãè©äŸ¡ãããšãããé¡äŒŒã®çµæãåŸãããããªãã¡ãã©ããã€ã·ã³ãé¡èã«çŽ°èæ°ãšæŽ»æ§ãåäžãããããšãã§ããããšã瀺ããã(å³3B)ã
ããèæ§å¹¹çŽ°èã®å¿ç现èãžã®ååã¯éåžžã«è€éã§è匱ãªéçšã§ãæ§ã ãªç°å¢èŠçŽ ã®å€åããã³çŽ°èç¶æ ã®å€åã«éåžžã«ææã§ãããç¹ã«åå±€é«å¯åºŠååæ¹æ³ã¯ãEBååæ³ãšæ¯ã¹ããã粟確ãªèª¿ç¯ã«äŸåããèªå·±åæ³ãµã€ãã«ã€ã³ã®æ¿åºŠã¬ãã«ã«ãäŸåããã©ããªå¹²æžãååå¹çã®äœäžãã²ããŠã¯å®å šãªå€±æã«ã€ãªããå¯èœæ§ãããã
ååã®éçšã«ãããŠãã©ããã€ã·ã³ã§åŠçããã现èã¯CHIRåŠç矀ã«å¯ŸããŠåœ¢æ äžã¯ããç·»å¯ã§é µçŽ æ¶åã®æããé·ãæéãå¿ èŠã§ããã€é·æéã®å¹é€éçšã§æµ®ãæ»äº¡çŽ°èãããå°ãªãããã®çŸè±¡ã確èªããããã«ãçºæè ã¯å¹é€éçšã§çŽ°èæ°ããã³çŽ°è掻æ§ã®å€åãæ€åºããã
ããããDMSOãCHIRããã³CHIR+ã©ããã€ã·ã³ãšãã3çš®é¡ã®åŠçæ¡ä»¶ã§é¢é£æ€åºãè¡ã£ãã现èèšæ°ãããDMSO溶åªã§åŠçãããå¯Ÿç §çŽ°èã«å¯ŸããCHIRã¯æåã®3æ¥ã§å¹¹çŽ°èæ°ã®å¢å ãæ©ãããããšãã§ãããã4æ¥ç®ã«çŽ°èæ°ã®æ¥æ¿ãªäœäžãæžå°ããããšãã§ããïŒ4æ¥ç®ã«å¹é€æ¶²ã亀æããããã幹现èã¯å¹é€ç°å¢ã®æ¥æ¿ãªå€åã«ãã£ãŠå€§éã«æ»äº¡ããïŒãçµæãããã©ããã€ã·ã³ã¯ããã«çŽ°èæ°ãå¢å ããããã€çŽ°èæ°ã®äœäžãæžå°ããããšãã§ããããšãèŠåºãããïŒå³3AïŒã
CCK-8ãããã§çŽ°èã«ãããè±æ°ŽçŽ é µçŽ ã®æŽ»æ§ãæ€åºããããšã«ãã£ãŠçŽ°èã®å¢æ®ã¬ãã«ãšçŽ°è掻æ§ãè©äŸ¡ãããšãããé¡äŒŒã®çµæãåŸãããããªãã¡ãã©ããã€ã·ã³ãé¡èã«çŽ°èæ°ãšæŽ»æ§ãåäžãããããšãã§ããããšã瀺ããã(å³3B)ã
å®æœäŸ6 ã©ããã€ã·ã³ã®å¹¹çŽ°èã«å¯Ÿãã圱é¿
6.1 现èåšæåæããã³BrdU现èå¢æ®æ€åºå®éšã«ããç°ãªãå°ååçµæç©ã§åŠçãããå Žåã®å¹¹çŽ°èã®å¢æ®é床ã®æ€åº
BrdU现èå¢æ®ã®æ€åºïŒ
现èãåéããåã«10ÎŒM BrdU(Sigma-Aldrich)ãå ¥ããŠ1æéã€ã³ãã¥ããŒãããã现èãæ¶åãã300gã§5åéé å¿ãã现èãåéãã0.5ïŒ BSAãå«ãPBS(æŽæµæ¶²)ã§å®€æž©ã§1åæŽæµãã1ml PBSã§åæžæ¿ããããæ¯ãšãããªãã3mlã®å·ãããŠããããšã¿ããŒã«ãå ¥ãã宀枩ã§20åéåºå®åããé å¿ã§äžæž ãé€å»ãããPBSã§1åæŽæµããé å¿ã§äžæž ãé€å»ããæ²æ®¿ãã»ãããããã«äœåã軜ã匟ããã1mlã®æ°ãã調補ããå€æ§æ¶²(2M HCl)ããããåäžã«æ··åãã宀枩ã§20åé眮ããã1ml 0.1Mã®ããŠé žãããªãŠã (pH8.5)ãå ¥ããŠå®€æž©ã§2åéäžåããã1åæŽæµããæBrdUæäœ(BD Biosciences 1:50ã§åžé)ããããæäœã¯0.5ïŒ Tween20/0.5ïŒ BSA(Sigma-Aldrich)ãå«æããPBSã§èª¿è£œããããäžæ¬¡æäœãåžãåãã1mlã®æŽæµæ¶²ã§1åæŽæµããAlexa-488-æããŠã¹(1:1000)ãããã宀枩ã§20åéã€ã³ãã¥ããŒããããäºæ¬¡æäœãåžãåãã1åæŽæµãã0.5mlã®10ÎŒg/ml PI溶液ã§åæžæ¿ããã宀枩ã§30åéã€ã³ãã¥ããŒããããé å¿ã§äžæž ãé€å»ããæŽæµæ¶²ã§1åæŽæµããããŒãµã€ãã¡ããªãŒãè¡ã£ãã
çµæãããDMSOå¯Ÿç §çŸ€ã«å¯ŸããCHIRã¯å ãã«Sæã«ãã现èã®æ¯çãšBrdUéœæ§çŽ°èã®æ¯çãå¢å ãããããã©ããã€ã·ã³ã¯ãã®ä¿é²äœçšã匱åãã幹现èã®å¢æ®é床ãDMSO矀ã«é¡äŒŒããããã«ãããããšã瀺ããã(å³4Aã4B)ãããã¯mTORã现èå¢æ®ãæ¯æããããã©ããã€ã·ã³ã现èå¢æ®ãæå¶ãããšããåŸæ¥ã®èŠ³å¿µãšäžèŽããã
6.1 现èåšæåæããã³BrdU现èå¢æ®æ€åºå®éšã«ããç°ãªãå°ååçµæç©ã§åŠçãããå Žåã®å¹¹çŽ°èã®å¢æ®é床ã®æ€åº
BrdU现èå¢æ®ã®æ€åºïŒ
现èãåéããåã«10ÎŒM BrdU(Sigma-Aldrich)ãå ¥ããŠ1æéã€ã³ãã¥ããŒãããã现èãæ¶åãã300gã§5åéé å¿ãã现èãåéãã0.5ïŒ BSAãå«ãPBS(æŽæµæ¶²)ã§å®€æž©ã§1åæŽæµãã1ml PBSã§åæžæ¿ããããæ¯ãšãããªãã3mlã®å·ãããŠããããšã¿ããŒã«ãå ¥ãã宀枩ã§20åéåºå®åããé å¿ã§äžæž ãé€å»ãããPBSã§1åæŽæµããé å¿ã§äžæž ãé€å»ããæ²æ®¿ãã»ãããããã«äœåã軜ã匟ããã1mlã®æ°ãã調補ããå€æ§æ¶²(2M HCl)ããããåäžã«æ··åãã宀枩ã§20åé眮ããã1ml 0.1Mã®ããŠé žãããªãŠã (pH8.5)ãå ¥ããŠå®€æž©ã§2åéäžåããã1åæŽæµããæBrdUæäœ(BD Biosciences 1:50ã§åžé)ããããæäœã¯0.5ïŒ Tween20/0.5ïŒ BSA(Sigma-Aldrich)ãå«æããPBSã§èª¿è£œããããäžæ¬¡æäœãåžãåãã1mlã®æŽæµæ¶²ã§1åæŽæµããAlexa-488-æããŠã¹(1:1000)ãããã宀枩ã§20åéã€ã³ãã¥ããŒããããäºæ¬¡æäœãåžãåãã1åæŽæµãã0.5mlã®10ÎŒg/ml PI溶液ã§åæžæ¿ããã宀枩ã§30åéã€ã³ãã¥ããŒããããé å¿ã§äžæž ãé€å»ããæŽæµæ¶²ã§1åæŽæµããããŒãµã€ãã¡ããªãŒãè¡ã£ãã
çµæãããDMSOå¯Ÿç §çŸ€ã«å¯ŸããCHIRã¯å ãã«Sæã«ãã现èã®æ¯çãšBrdUéœæ§çŽ°èã®æ¯çãå¢å ãããããã©ããã€ã·ã³ã¯ãã®ä¿é²äœçšã匱åãã幹现èã®å¢æ®é床ãDMSO矀ã«é¡äŒŒããããã«ãããããšã瀺ããã(å³4Aã4B)ãããã¯mTORã现èå¢æ®ãæ¯æããããã©ããã€ã·ã³ã现èå¢æ®ãæå¶ãããšããåŸæ¥ã®èŠ³å¿µãšäžèŽããã
6.2 ã©ããã€ã·ã³ã®ã¢ãããŒã·ã¹ã¬ãã«ã«å¯Ÿãã圱é¿ã®æ€åº
ã«ã¹ããŒãŒ3/7掻æ§æ€åºïŒæ¬å®éšã§ã«ã¹ããŒãŒ-Glo 3/7ããã(Promega)ã䜿çšãããã现èã96ãŠã§ã«ãã¬ãŒãã«æ¥çš®ããçžå¿ããå°ååã§2æ¥åŠçããåŸãäºåã«æ··åãããåå¿æ¶²ãå ¥ããååã«å解ãããåŸã22âã§20åéã€ã³ãã¥ããŒãããè£ çœ®ã«ã»ããããŠèå 匷床ãæ€åºãããã詳现ã¯èª¬ææžãåç §ããã
ã¢ããã·ã³V/PIæè²ïŒæ¬å®éšã§ã¢ããã·ã³V/PIããã(Roche)ã䜿çšãããã现èã24ãŠã§ã«ãã¬ãŒãã§å¹é€ããæå®ã®æç¹ã§accutaseã§å现èã«æ¶åããPBSã§1åæŽæµããã¢ããã·ã³VãšPIã®æè²æ¶²ãå ¥ããŠ10åéã€ã³ãã¥ããŒãããå ãé¿ããããã«æ³šæãã5åäœç©ã®ã€ã³ãã¥ããŒã液ãå ¥ããŠåžéããåå¿ãåæ¢ãããããããŒãµã€ãã¡ããªãŒãè¡ã£ãããå±èµ·å ã¯488nmãš518nmã§ãæŸåºå ã¯488ã540nmãš617nmã§ãã£ãã
ã¢ãããŒã·ã¹ã®äžçªäžæµã®æšèã¿ã³ãã¯è³ªParpã®åæãããæåã®4æ¥ã®CHIRåŠçéçšã§å¹é€æéãé·ããªããšãParpã®åæãã³ããå¢å ãã4æ¥ç®ã«ããŒã¯å€ã«éããããšã瀺ããããããããã©ããã€ã·ã³ã«ããåŠçã¯é¡èã«Parpã®åæãæå¶ããæåã®3æ¥ã¯ã»ãšãã©æ€åºãããã4æ¥ç®ã ãã«çŸããïŒå³4CïŒãã«ã¹ããŒãŒ3ã6ã7ã¯ã¢ãããŒã·ã¹ã®å®è¡ã¿ã³ãã¯è³ªã§ãäž»ã«çŽ°èæ žå ã现è質ã«ãããæ§é ã¿ã³ãã¯è³ªããã³èª¿ç¯ã¿ã³ãã¯è³ªã®åæãæ åœããã
ã«ã¹ããŒãŒ3/7掻æ§æ€åºïŒæ¬å®éšã§ã«ã¹ããŒãŒ-Glo 3/7ããã(Promega)ã䜿çšãããã现èã96ãŠã§ã«ãã¬ãŒãã«æ¥çš®ããçžå¿ããå°ååã§2æ¥åŠçããåŸãäºåã«æ··åãããåå¿æ¶²ãå ¥ããååã«å解ãããåŸã22âã§20åéã€ã³ãã¥ããŒãããè£ çœ®ã«ã»ããããŠèå 匷床ãæ€åºãããã詳现ã¯èª¬ææžãåç §ããã
ã¢ããã·ã³V/PIæè²ïŒæ¬å®éšã§ã¢ããã·ã³V/PIããã(Roche)ã䜿çšãããã现èã24ãŠã§ã«ãã¬ãŒãã§å¹é€ããæå®ã®æç¹ã§accutaseã§å现èã«æ¶åããPBSã§1åæŽæµããã¢ããã·ã³VãšPIã®æè²æ¶²ãå ¥ããŠ10åéã€ã³ãã¥ããŒãããå ãé¿ããããã«æ³šæãã5åäœç©ã®ã€ã³ãã¥ããŒã液ãå ¥ããŠåžéããåå¿ãåæ¢ãããããããŒãµã€ãã¡ããªãŒãè¡ã£ãããå±èµ·å ã¯488nmãš518nmã§ãæŸåºå ã¯488ã540nmãš617nmã§ãã£ãã
ã¢ãããŒã·ã¹ã®äžçªäžæµã®æšèã¿ã³ãã¯è³ªParpã®åæãããæåã®4æ¥ã®CHIRåŠçéçšã§å¹é€æéãé·ããªããšãParpã®åæãã³ããå¢å ãã4æ¥ç®ã«ããŒã¯å€ã«éããããšã瀺ããããããããã©ããã€ã·ã³ã«ããåŠçã¯é¡èã«Parpã®åæãæå¶ããæåã®3æ¥ã¯ã»ãšãã©æ€åºãããã4æ¥ç®ã ãã«çŸããïŒå³4CïŒãã«ã¹ããŒãŒ3ã6ã7ã¯ã¢ãããŒã·ã¹ã®å®è¡ã¿ã³ãã¯è³ªã§ãäž»ã«çŽ°èæ žå ã现è質ã«ãããæ§é ã¿ã³ãã¯è³ªããã³èª¿ç¯ã¿ã³ãã¯è³ªã®åæãæ åœããã
ã«ã¹ããŒãŒ3/7ã«ã·ãã§ã©ãŒãŒã¬ããŒã¿ãŒãããã«ãã£ãŠå¹¹çŽ°èã®å
åšæ§ã«ã¹ããŒãŒ3/7ã®æŽ»æ§ãæ€åºãããšãããã©ããã€ã·ã³ã«ããåŠçã¯çŽ°èã«ãããã«ã¹ããŒãŒ3/7ã®æŽ»æ§ãCHIRã«ããåç¬åŠçã®ååã®ã¬ãã«ã«äœäžãããããšã瀺ããã(å³4D)ã
ã¢ããã·ã³V/PIäºéæè²å®éšã§ã¯ã3æ¥ç®ã®å¹é€çµäºæãDMSOåŠç矀ã§ã¯å¹³å31.4ïŒ ã®ã¢ããã·ã³Véœæ§ã®ã¢ãããŒã·ã¹çŽ°èããããCHIRåŠç矀ã§ã¯25.8ïŒ ã®ã¢ããã·ã³Véœæ§ã®ã¢ãããŒã·ã¹çŽ°èããã£ãããCHIR+ã©ããã€ã·ã³åŠç矀ã§ã¯çŽ15.5ïŒ ãããªãã¢ããã·ã³Véœæ§çŽ°èããã£ãããšã瀺ããã(å³4E)ã4æ¥ç®ã«ãRPMI/B27ååå¹å°ã亀æããŠ24æéå¹é€ããåŸãåã®DMSOããæ·»å ãããªãã£ã现è矀ã§ã¯å€§éã®æ»äº¡ãçŸããçŽ80ïŒ ã®çŽ°èãæ»äº¡ãããCHIRåŠç矀ã§ãååè¿ãã®æ»äº¡ããã£ãããããã«ã©ããã€ã·ã³ãæ·»å ãããå Žååæ§ã«é¡èã«çŽ°èæ»äº¡ã®æ¯çãæžå°ããããšãã§ãã(å³4F)ã
äžèšçµæãããã©ããã€ã·ã³ã¯ååéçšã«ãããŠå¹¹çŽ°èã«å¯ŸããŠä¿è·äœçšãæãããã¢ãããŒã·ã¹ã®å¹ççãªååã«å¯Ÿããé»å®³ãæžå°ããããšãã§ããããã¯ã©ããã€ã·ã³ãå¿ç现èã®åéãåäžãããåå ã§ãããããšã瀺ãããã
ã¢ããã·ã³V/PIäºéæè²å®éšã§ã¯ã3æ¥ç®ã®å¹é€çµäºæãDMSOåŠç矀ã§ã¯å¹³å31.4ïŒ ã®ã¢ããã·ã³Véœæ§ã®ã¢ãããŒã·ã¹çŽ°èããããCHIRåŠç矀ã§ã¯25.8ïŒ ã®ã¢ããã·ã³Véœæ§ã®ã¢ãããŒã·ã¹çŽ°èããã£ãããCHIR+ã©ããã€ã·ã³åŠç矀ã§ã¯çŽ15.5ïŒ ãããªãã¢ããã·ã³Véœæ§çŽ°èããã£ãããšã瀺ããã(å³4E)ã4æ¥ç®ã«ãRPMI/B27ååå¹å°ã亀æããŠ24æéå¹é€ããåŸãåã®DMSOããæ·»å ãããªãã£ã现è矀ã§ã¯å€§éã®æ»äº¡ãçŸããçŽ80ïŒ ã®çŽ°èãæ»äº¡ãããCHIRåŠç矀ã§ãååè¿ãã®æ»äº¡ããã£ãããããã«ã©ããã€ã·ã³ãæ·»å ãããå Žååæ§ã«é¡èã«çŽ°èæ»äº¡ã®æ¯çãæžå°ããããšãã§ãã(å³4F)ã
äžèšçµæãããã©ããã€ã·ã³ã¯ååéçšã«ãããŠå¹¹çŽ°èã«å¯ŸããŠä¿è·äœçšãæãããã¢ãããŒã·ã¹ã®å¹ççãªååã«å¯Ÿããé»å®³ãæžå°ããããšãã§ããããã¯ã©ããã€ã·ã³ãå¿ç现èã®åéãåäžãããåå ã§ãããããšã瀺ãããã
å®æœäŸ7 ã»ãã®ååç©ã®çµã¿åããã«ããå¿ç现èã®èªå°
ããããmTORã·ã°ãã«çµè·¯æå¶å€ã§ããã©ããã€ã·ã³ã®é¡äŒŒç©ã®RAD001ãKU0063794ããã³AZD8055ãWntã·ã°ãã«çµè·¯ä¿é²å€ã§ããCHIRãšçµã¿åãããWntã·ã°ãã«çµè·¯ä¿é²å€ã§ããBIOãã©ããã€ã·ã³ãŸãã¯ã©ããã€ã·ã³ã®é¡äŒŒç©ã§ããRAD001ãšçµã¿åãããå¿ç现èã®ååç¶æ³ã芳å¯ããã
æ¹æ³ã¯å®æœäŸ2ã®èªå°ã®ãããã³ãŒã«ãšåæ§ã§ããã®çµæãåæ§ã®å®éšæ¡ä»¶ã«ãããŠãååç©ã®çµã¿åããã§ããCHIRãšRAD001ãCHIRãšKU0063794ãCHIRãšAZD8055ã¯å¿ç现èãçæãããå¿ç现èã®ååçã¯ãããã78.8ïŒ ã68.75ïŒ ã74.43ïŒ ã§ãã£ãããšãèŠåºããã(å³5a)ã
ãããŠãååç©ã®çµã¿åããã§ããBIOãšã©ããã€ã·ã³ãBIOãšRAD001ãå¿ç现èãçæãããå¿ç现èã®ååçã¯ãããã83.47ïŒ ã82.9ïŒ ã§ãã£ãïŒå³5bïŒã
ãããã®ç²Ÿè£œãããååç©ã«ãã£ãŠèªå°ãããå¿ç现èã¯ãæçã®å¿ç现èã®åœ¢æ ãæã¡ããã€æ£åžžã®å¿çæ©èœãçºæ®ããæ§é åºç€ãæããã
ãã®ãããã»ãã®mTORã·ã°ãã«çµè·¯æå¶å€ãšWntã·ã°ãã«çµè·¯ä¿é²å€ïŒããšãã°CHIRãBIOïŒã®çµã¿åãããå¹ççã«å¿ç现èã®ååãèªå°ãããã€ååããå¿ç现èã¯æçã®å¿ç现èã®ç¹åŸŽãæããã
ããããmTORã·ã°ãã«çµè·¯æå¶å€ã§ããã©ããã€ã·ã³ã®é¡äŒŒç©ã®RAD001ãKU0063794ããã³AZD8055ãWntã·ã°ãã«çµè·¯ä¿é²å€ã§ããCHIRãšçµã¿åãããWntã·ã°ãã«çµè·¯ä¿é²å€ã§ããBIOãã©ããã€ã·ã³ãŸãã¯ã©ããã€ã·ã³ã®é¡äŒŒç©ã§ããRAD001ãšçµã¿åãããå¿ç现èã®ååç¶æ³ã芳å¯ããã
æ¹æ³ã¯å®æœäŸ2ã®èªå°ã®ãããã³ãŒã«ãšåæ§ã§ããã®çµæãåæ§ã®å®éšæ¡ä»¶ã«ãããŠãååç©ã®çµã¿åããã§ããCHIRãšRAD001ãCHIRãšKU0063794ãCHIRãšAZD8055ã¯å¿ç现èãçæãããå¿ç现èã®ååçã¯ãããã78.8ïŒ ã68.75ïŒ ã74.43ïŒ ã§ãã£ãããšãèŠåºããã(å³5a)ã
ãããŠãååç©ã®çµã¿åããã§ããBIOãšã©ããã€ã·ã³ãBIOãšRAD001ãå¿ç现èãçæãããå¿ç现èã®ååçã¯ãããã83.47ïŒ ã82.9ïŒ ã§ãã£ãïŒå³5bïŒã
ãããã®ç²Ÿè£œãããååç©ã«ãã£ãŠèªå°ãããå¿ç现èã¯ãæçã®å¿ç现èã®åœ¢æ ãæã¡ããã€æ£åžžã®å¿çæ©èœãçºæ®ããæ§é åºç€ãæããã
ãã®ãããã»ãã®mTORã·ã°ãã«çµè·¯æå¶å€ãšWntã·ã°ãã«çµè·¯ä¿é²å€ïŒããšãã°CHIRãBIOïŒã®çµã¿åãããå¹ççã«å¿ç现èã®ååãèªå°ãããã€ååããå¿ç现èã¯æçã®å¿ç现èã®ç¹åŸŽãæããã
åæç®ãããããåç¬ã«åŒçšãããããã«ãæ¬çºæã«ä¿ããã¹ãŠã®æç®ã¯æ¬åºé¡ã§åèãšããŠåŒçšããããŸããæ¬çºæã®äžèšã®å
容ãèªã¿çµãã£ãåŸãåœæ¥è
ãæ¬çºæãåçš®ã®å€åãä¿®æ£ãããããšãã§ãããããããã®ç䟡ã®åœ¢æ
ã®ãã®ã¯æ¬çºæã®è«æ±ã®ç¯å²ã«å«ãŸããããšãç解ãããã¯ãã§ããã
Claims (10)
- ïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ã
ïŒiiïŒWntçµè·¯ä¿é²å€ãããã³
ïŒiiiïŒä»»æã«è¬åŠçã«èš±å®¹ãããæ äœã
ãšããæåãããªãããšãç¹åŸŽãšããã幹现èã®å¿ç现èãžã®ååãä¿é²ããããã®ãå°ååååç©çµæç©ã - åèšmTORã·ã°ãã«çµè·¯æå¶å€ããã©ããã€ã·ã³(Rapamycin)ããšãããªã ã¹(RAD001)ãKU-0063794ãAZD8055ããã ã·ããªã ã¹(Temsirolimus)ãINK128ããªããããªã ã¹(Ridaforolimus)ãããã³ãããã®çµã¿åãããããªã矀ããéžã°ããããšãç¹åŸŽãšãããè«æ±é ïŒã«èšèŒã®å°ååååç©çµæç©ã
- åèšWntçµè·¯ä¿é²å€ããCHIR99021ãBIOããŸãã¯ãããã®çµã¿åãããå«ãããšãç¹åŸŽãšãããè«æ±é ïŒã«èšèŒã®å°ååååç©çµæç©ã
- äœå€ã§éæ²»ççã«å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããæ¹æ³ã§ãã£ãŠãïŒaïŒïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãããã³ïŒiiïŒWntçµè·¯ä¿é²å€ãããªããååèªå°ååç©ã®çµã¿åããã®ååšäžã«ãããŠãå¹é€ç³»ã§å¹¹çŽ°èç³»ãå¹é€ããããšã«ãã£ãŠãåèšã®å¿ç现èãåŸãå·¥çšãå«ãããšãç¹åŸŽãšãããåèšæ¹æ³ã
- ïŒbïŒå·¥çšïŒaïŒã§åŸãããå¿ç现èãæ¿çž®ããŠç²Ÿè£œããå·¥çšãããã«å«ãããšãç¹åŸŽãšãããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- è«æ±é ïŒã«èšèŒã®æ¹æ³ã«ãã£ãŠè£œé ãããïŒiïŒå¿ç现èã®ç¹ç°çæ§é éºäŒåãé«åºŠã«çºçŸãããããšãããã³ïŒiiïŒã€ãªã³ãã£ãã«éºäŒåãé«åºŠã«çºçŸãããããšããããªã矀ããéžã°ãã1ã€ãŸãã¯è€æ°ã®ç¹åŸŽãæããããšãç¹åŸŽãšãããå¿ç现èã
- è«æ±é ïŒã«èšèŒã®å°ååååç©çµæç©ãå«ãããšãç¹åŸŽãšãããå¿ç现èã®ååãä¿é²ãããããã
- å¿èçŸæ£ãäºé²ããã³ïŒãŸãã¯æ²»çããè¬ç©çµæç©ã®è£œé ã®ããã®ãè«æ±é ïŒã«èšèŒã®å¿ç现èã®äœ¿çšã
- è«æ±é ïŒã«èšèŒã®å¿ç现èãå«ãããšãç¹åŸŽãšãããçµæç©ã
- ïŒiïŒmTORã·ã°ãã«çµè·¯æå¶å€ãããã³
ïŒiiïŒWntçµè·¯ä¿é²å€ã
ãšããæåãããªãããšãç¹åŸŽãšããã幹现èã®å¿ç现èãžã®ååãä¿é²ããããã®ãå°ååååç©çµæç©ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610038160.4A CN106987555B (zh) | 2016-01-20 | 2016-01-20 | é«æ诱富人å€èœå¹²ç»èåå¿èç»èååçå°ååååç©ç»åç© |
CN201610038160.4 | 2016-01-20 | ||
PCT/CN2017/070989 WO2017124963A1 (zh) | 2016-01-20 | 2017-01-12 | é«æ诱富人å€èœå¹²ç»èåå¿èç»èååçå°ååååç©ç»åç© |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2019506157A JP2019506157A (ja) | 2019-03-07 |
JP2019506157A5 true JP2019506157A5 (ja) | 2020-02-06 |
JP6713159B2 JP6713159B2 (ja) | 2020-06-24 |
JP6713159B6 JP6713159B6 (ja) | 2020-07-22 |
Family
ID=59361448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018537795A Active JP6713159B6 (ja) | 2016-01-20 | 2017-01-12 | å¹ççã«ããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããå°ååååç©çµæç© |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3406248A4 (ja) |
JP (1) | JP6713159B6 (ja) |
CN (1) | CN106987555B (ja) |
CA (1) | CA3012064C (ja) |
HK (1) | HK1258312A1 (ja) |
WO (1) | WO2017124963A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11850266B2 (en) * | 2019-06-06 | 2023-12-26 | President And Fellows Of Harvard College | Cardiomyocytes and compositions and methods for producing the same |
KR102200612B1 (ko) * | 2020-04-29 | 2021-02-01 | ë€ìŽì²ë°ìŽì€í(죌) | íìì ì íì± ì ì ì륌 í¬íšíë í ëŒí ë§ ì ê±°ì© dna 구조첎 |
CN111876377A (zh) * | 2020-07-07 | 2020-11-03 | æ¹ååžèå€§åŠ | äžç§åºäºèªå¬çå¹²ç»èå¿èç»è诱富ååæ¹æ³åå ¶åºçš |
CN112359012B (zh) * | 2020-10-22 | 2022-11-25 | äžåœç§åŠé¢æ°Žççç©ç 究æ | 诱富å€èœå¹²ç»èååå¶å€å¿èç£èå ç®ç»èçæ¹æ³åå ¶åºçš |
CN113249310B (zh) * | 2021-05-17 | 2022-10-11 | æ¹åå€§åŠ | äžç§æå±æ§å€èœå¹²ç»è诱富åå䞺å¿èç»èçæ¹æ³ååºçš |
WO2024041645A1 (zh) * | 2022-08-25 | 2024-02-29 | åäº¬å€§åŠ | çšäºå¶å€å¿èç»èçååç©åå ¶çšé |
CN117511976A (zh) * | 2023-11-08 | 2024-02-06 | 西ååæç§æå€§åŠ | äžç§Tnnt2 H2B-mCherryæ¥åç»èç³»çæ建æ¹æ³ååºçš |
CN117467599B (zh) * | 2023-12-27 | 2024-03-29 | 广äžçåäžç§åŠé¢åšç©ç§åŠç 究æ | äžç§éçŒçšéž¡æ§è ºäœç»è䞺鞡å€èœå¹²ç»èçååŠè¯±å¯ŒååéçŒçšæ¹æ³ |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
WO2013111875A1 (ja) * | 2012-01-27 | 2013-08-01 | åœç«å€§åŠæ³äººäº¬éœå€§åŠ | å€èœæ§å¹¹çŽ°èã®å¿çååèªå°æ³ |
CA2886396C (en) * | 2012-07-23 | 2023-08-22 | Institute Of Biophysics, Chinese Academy Of Sciences | Method for inducing pluripotent stem cells to differentiate into ventricular cardiomyocytes in vitro |
SG11201500918YA (en) * | 2012-08-07 | 2015-04-29 | Singapore Health Serv Pte Ltd | Method, combination and/or composition for inducing cardiomyocyte differentation |
US20150329821A1 (en) * | 2012-10-19 | 2015-11-19 | Agency For Science, Technology And Research | Methods of differentiating stem cells into one or more cell lineages |
-
2016
- 2016-01-20 CN CN201610038160.4A patent/CN106987555B/zh active Active
-
2017
- 2017-01-12 EP EP17740994.3A patent/EP3406248A4/en active Pending
- 2017-01-12 WO PCT/CN2017/070989 patent/WO2017124963A1/zh active Application Filing
- 2017-01-12 JP JP2018537795A patent/JP6713159B6/ja active Active
- 2017-01-12 CA CA3012064A patent/CA3012064C/en active Active
-
2019
- 2019-01-15 HK HK19100679.7A patent/HK1258312A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6713159B6 (ja) | å¹ççã«ããå€èœæ§å¹¹çŽ°èã®å¿ç现èãžã®ååãèªå°ããå°ååååç©çµæç© | |
JP2019506157A5 (ja) | ||
US20220340877A1 (en) | Method for Inducing Pluripotent Stem Cells to Differentiate into Ventricular Cardiomyocytes In Vitro | |
JP4964121B2 (ja) | è¡ç®¡å ç®åé§çŽ°èã®çäœå€å¢å¹ æ¹æ³ | |
JP2020162608A (ja) | å¿å€è现èã圢æããããã®æ¹æ³åã³çµæç© | |
Suliman et al. | Heme oxygenase-1/carbon monoxide system and embryonic stem cell differentiation and maturation into cardiomyocytes | |
Garita-HernÃndez et al. | Hypoxia increases the yield of photoreceptors differentiating from mouse embryonic stem cells and improves the modeling of retinogenesis in vitro | |
US20230046238A1 (en) | Composition and use thereof | |
US20200009197A1 (en) | Compositions and methods for the reprogramming of cells into cardiomyocytes | |
US11788060B2 (en) | Small molecule compound composition that efficiently induces differentiation of human pluripotent stem cells into myocardial cells | |
JP7154586B2 (ja) | 幹现èã®å¹èœæ¹åã®ããã®çµæç©åã³æ¹æ³ | |
EP2581443B1 (en) | Method for differentiating human neural progenitor cells into dopaminergic neurons, and medium for differentiation thereof | |
US11712451B2 (en) | Agent for promoting wound healing comprising platelet-like cell co-expressing platelet surface antigen and mesenchymal cell surface antigen | |
Cheng et al. | Rho-associated kinase inhibitors promote the cardiac differentiation of embryonic and induced pluripotent stem cells | |
Tan et al. | Generation of clinicalâgrade functional cardiomyocytes from human embryonic stem cells in chemically defined conditions | |
IL215328A (en) | Method of immersing cell death in pluripotent stem cells and differentiated cells other than cardiomyocytes | |
KR102281535B1 (ko) | ì€êž°ìží¬ ì ë ê°ì€ê°ë žìŽëì ì ì ë° ì ïŒí íì°ë³ ìží¬ì¹ë£ì ë¡ìì ì©ë | |
KR20130085863A (ko) | ì€ê°ìœ ì€êž°ìží¬ì ìŽë ì ëì© ì¡°ì±ë¬Œ | |
JP6042099B2 (ja) | 现èå¢æ®æå¶å€ | |
KR20200126927A (ko) | 첎ìží¬ë¡ë¶í° ì·ì¥ ë² í ìží¬ë¥Œ ì§ì ë¶íìí€ë ë°©ë² ë° ë¶í ì¡°ì±ë¬Œ | |
JP6419455B2 (ja) | æçãã¹ã现èã®äœè£œæ¹æ³åã³åŸãããæçãã¹ã现è | |
JP2024024550A (ja) | æªåå幹现èã®çŽ°èæ»èªå°å€ãåã³åå现èã®çŽåæ¹æ³ |